

1 TITLE PAGE



VERTEX PHARMACEUTICALS INCORPORATED

Clinical Study Protocol

**A Phase 2, Randomized, Double-blind, Placebo-controlled,
Multi-dose Study Evaluating the Efficacy and Safety of
VX-548 for Acute Pain After an Abdominoplasty**

Vertex Study Number: VX21-548-102



Date of Protocol: 21 January 2022 (Version 4.0)

Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210-1862, USA

CONFIDENTIAL

This document contains confidential information. Any use, distribution, or disclosure without the prior written consent of Vertex Pharmaceuticals Incorporated is strictly prohibited except to the extent required under applicable laws or regulations. Persons to whom the information is disclosed must be informed that the information is confidential and may not be further disclosed by them.

Summary of Changes to the Protocol

The previous version of this protocol (Version 3.0, 10 September 2021) was amended to create the current version (Version 4.0, 21 January 2022). The protocol history is below.

Protocol History	
Version and Date of Protocol	Comments
Version 1.0, 08 June 2021	Original version
Version 2.0, 26 July 2021	To ensure subject safety and assess wound healing, clinical laboratory tests were added at 48 hours after the first dose and a focused physical examination was added at 48 hours after the first dose and at the Safety Follow-up Visit.
Version 3.0, 10 September 2021	<ul style="list-style-type: none"> • Clarified abdominoplasty procedure details • Increased the BMI upper limit from 35.0 to 38.0 kg/m² in inclusion criterion 4 to allow for participation of more subjects • Updated the permitted analgesic medications to provide adequate management of perioperative pain • Updated the contraceptive requirements based on negative genotoxicity data and to align with the Clinical Trials Facilitation and Coordination Group guidance related to contraception in clinical trials: <ul style="list-style-type: none"> ○ Reduced the required contraceptive period for subjects and their partners from 90 to 30 days after the last study drug dose. ○ Included hormone-releasing intrauterine devices as an acceptable method of contraception for female subjects.
Version 4.0, 21 January 2022	Current version

Key changes in the current version of the protocol are summarized below.

Change and Rationale	Affected Sections
Added that pharmacokinetic blood samples may also be used for evaluations of other study medications, including acetaminophen and hydrocodone.	Section 11.2.1

Typographical and administrative changes were also made to improve the clarity of the document.

2 PROTOCOL SYNOPSIS

Title	A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-dose Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
Brief Title	A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
Clinical Phase and Clinical Study Type	Phase 2, efficacy and safety
Objectives	<p><u>Primary Objective</u></p> <ul style="list-style-type: none"> • To evaluate the efficacy of VX-548 doses in treating acute pain after an abdominoplasty <p><u>Secondary Objective</u></p> <ul style="list-style-type: none"> • To evaluate the safety and tolerability of VX-548 <p><u>Other Objective</u></p> <ul style="list-style-type: none"> • To evaluate the pharmacokinetics (PK) of VX-548 and its metabolite, [REDACTED]
Endpoints	<p><u>Primary Endpoint</u></p> <ul style="list-style-type: none"> • Time-weighted sum of the pain intensity difference (SPID) as recorded on a Numeric Pain Rating Scale (NPRS) at rest 0 to 48 hours (SPID_{r0-48}) after the first dose of study drug <p><u>Secondary Endpoints</u></p> <ul style="list-style-type: none"> • Time-weighted SPID as recorded on an NPRS at rest 0 to 24 hours (SPID_{r0-24}) after the first dose of study drug • Proportions of subjects with $\geq 30\%$, $\geq 50\%$, and $\geq 70\%$ reduction in NPRS at rest at 48 hours after the first dose of study drug • Safety and tolerability based on the incidence and type of adverse events (AEs), changes from baseline in clinically significant laboratory test results, vital signs, and ECGs <p><u>Other Endpoints</u></p> <ul style="list-style-type: none"> • Time-weighted SPID as recorded on an NPRS during movement 8 to 24 hours (SPID_{m8-24}) and 8 to 48 hours (SPID_{m8-48}) after the first dose of study drug • Time to onset of “confirmed perceptible pain relief” and “meaningful pain relief” after the first dose of study drug • Proportions of subjects with $\geq 30\%$, $\geq 50\%$, and $\geq 70\%$ reduction in NPRS at rest at 24 hours after the first dose of study drug • Patient Global Assessment (PGA) of study drug at 48 hours after the first dose of study drug • Percentage of subjects using rescue medication, and total rescue medication usage, 0 to 48 hours after the first dose of study drug • PK parameter estimates of VX-548 and its metabolite, [REDACTED]
Number of Subjects	Approximately 256 subjects
Study Population	Male or female subjects, 18 through 75 years of age (inclusive), with pain that is ≥ 4 on the NPRS at rest and moderate or severe on a Verbal Categorical Rating Scale (VRS) at rest after an abdominoplasty


- Investigational Drug** Active substance: VX-548
 Activity: Nav1.8 inhibitor
 Strength and route of administration: 10-mg tablets and matching placebo for oral administration
- Reference Drug** Active substance: hydrocodone bitartrate/acetaminophen (HB/APAP)
 Activity: opioid analgesic
 Strength and route of administration: 5-mg/325-mg capsules and matching placebo for oral administration
- Study Duration** Excluding the Screening Period, each subject will participate in the study for 3 days plus a Safety Follow-up Visit 14 ± 2 days after the last dose of study drug.

Study Design This is a Phase 2, randomized, double-blind, placebo-controlled, 4-arm, parallel study design evaluating the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty (Figure 2-1).

On Day 1, subjects will undergo a standard (“full”) abdominoplasty procedure (as defined in Section 8.1). After surgery completion, a subject will be randomized to 1 of 4 treatment groups if (1) the subject requests the first dose of study drug for pain relief, (2) the subject’s pain is moderate or severe on the VRS at rest, and (3) the subject’s pain is ≥4 on the NPRS at rest. If a subject does not meet the VRS and NPRS criteria within 4 hours of surgery completion, the subject will not be eligible for this study.

Approximately 256 subjects will be randomized 1:1:1:1 to 4 treatment groups: high-dose VX-548 (100 mg/50 mg every 12 hours [q12h]); low-dose VX-548 (60 mg/30 mg q12h); HB/APAP (opioid reference); or placebo (Table 2-1). Randomization will be stratified by site and baseline NPRS at rest (<8 versus ≥8). To maintain the blind, all subjects will receive the same number of tablets and/or capsules every 6 hours (q6h) in a double-dummy design.

Figure 2-1 VX21-548-102 Study Design



CRU: clinical research unit; HB/APAP: hydrocodone bitartrate/acetaminophen; NPRS: Numeric Pain Rating Scale; VRS: Verbal Categorical Rating Scale

Notes: After surgery completion, a subject will be randomized to 1 of 4 treatment groups if (1) the subject requests the first dose of study drug for pain relief, (2) the subject’s pain is moderate or severe on the VRS at rest, and (3) the subject’s pain is ≥4 on the NPRS at rest. If a subject does not meet the VRS and NPRS criteria within 4 hours of surgery completion, the subject will not be eligible for this study.

Table 2-1 VX21-548-102 Treatment Groups

Treatment	Active Dose	Number of Subjects
VX-548 (high dose)	100 mg first dose, then 50 mg q12h	64
VX-548 (low dose)	60 mg first dose, then 30 mg q12h	64
HB/APAP	5 mg/325 mg q6h	64
Placebo		64

HB/APAP: hydrocodone bitartrate/acetaminophen; q6h: every 6 hours; q12h: every 12 hours

Note: To maintain the blind, all subjects will receive the same number of tablets and/or capsules q6h in a double-dummy design. VX-548 active and/or VX-548 placebo will be administered to all subjects q12h: 0 hours (first dose) and at 12, 24 and 36 hours after the first dose of study drug. HB/APAP active or HB/APAP placebo will be administered to all subjects q6h: 0 hours (first dose) and at 6, 12, 18, 24, 30, 36 and 42 hours after the first dose of study drug.

Subjects will report their pain intensity on the NPRS at rest at each scheduled time point through 48 hours after the first dose of study drug. Starting 8 hours after the first dose of study drug, subjects will also report their pain intensity on the NPRS during movement. In addition, pain intensity will be recorded on the NPRS at rest immediately before each administration of rescue medication.

Ibuprofen (400 mg orally q6h as needed) is permitted as a rescue medication for pain relief upon the subject's request starting any time after the first dose of study drug through 48 hours after the first dose of study drug. Subjects are encouraged to wait 90 minutes after the first dose of study drug to request rescue medication, and subjects should generally not receive rescue medication unless their NPRS at rest score is ≥ 4 .

Assessments Efficacy: NPRS at rest and during movement, double-stopwatch assessment, and use of rescue medications
Safety: adverse events (AEs), clinical laboratory assessments, clinical evaluation of vital signs, standard 12-lead ECGs, and physical examinations
PK: plasma PK parameters of VX-548 and its metabolite, [REDACTED]
Other: VRS at rest, PGA of study drug, and DNA blood sample (optional)

Statistical Analyses The sample size calculation is based on the comparison between VX-548 and placebo on the primary endpoint. Assuming a standardized effect size of 0.8 for VX-548 (high or low dose) compared to placebo, 54 evaluable subjects per group would provide at least 90% power at a 2-sided significance level of 0.05. This sample size would allow a minimal detectable standardized effect size of 0.38 to achieve statistical significance between VX-548 (high or low dose) and placebo. With this sample size, a two-sided 95% CI for the estimated standard effect size will extend 0.38 from the observed standardized effect size, assuming the CI is based on the large sample z statistic. To allow for withdrawal of up to 15% of randomized subjects over 48 hours of treatment, the study will enroll and randomize approximately 256 subjects in total.

The primary efficacy analysis will be based on an analysis of covariance (ANCOVA) model. The model will include SPID_{r0-48} as the dependent variable and treatment as a fixed effect, with stratification factors (i.e., site and baseline NPRS at rest) as covariates. If the model estimation does not converge, site will be removed from the model. The least squares means of difference versus placebo and the corresponding 95% CIs and *P* values will be presented.

3 SCHEDULE OF ASSESSMENTS

Schedules of assessments are in [Table 3-1](#), [Table 3-2](#), and [Table 3-3](#).

Table 3-1 Study VX21-548-102: Screening Through Admission

Event/Assessment ^a	Day -28 to Day -1	Day 1	Comments
	Screening Visit	Pre-procedure	
Outpatient visit	X		
CRU admission		X	Upon completion of pre-procedure eligibility assessments; Section 8 .
Informed consent	X		Section 13.2.3
Demographics	X		
Medical and surgical history	X		
History of drug and alcohol use	X		Section 8.2
Prior use of opioid medications	X	X	Any use within 12 months of the Screening Visit through admission will be recorded; Section 9.5 .
Vital signs	X	X	Complete after ≥5-minute rest; Section 11.5.3 .
Standard 12-lead ECG	X	X	Complete after ≥5-minute rest in the supine position. ECGs must be performed before blood draws or any procedures that may affect heart rate. Section 11.5.4 .
Complete PE	X		Section 11.5.3
Weight, height, and BMI	X		Weight and height will be measured with shoes off. BMI = weight (kg) / [height (cm/100)] ²
Serology (HBsAg, HCV Ab, and HIV-1/HIV-2 Abs)	X		Section 11.5.2
Serum β-hCG	X		All female subjects; Section 11.5.2 .
Serum FSH	X		Postmenopausal female subjects only; Section 11.5.5.1
Serum chemistry	X		Section 11.5.2
Hematology	X		Section 11.5.2
Coagulation	X		Section 11.5.2
Urinalysis	X		Section 11.5.2
Drug test	X	X	Urine; Section 11.5.2 . Day 1: Testing kit assessed by staff onsite.
Urine β-hCG		X	All female subjects of childbearing potential. Assessed by staff onsite. Section 11.5.2 .
Alcohol test		X	Urine, blood, or breath. Breath testing kit assessed by staff onsite. Section 11.5.2 .
Placebo and pain assessment video training	X	X	Section 11.4.1
Blood sampling for PK		X	Collect after completion of pre-procedure eligibility assessments; Section 11.2.1 .
Medications review	Continuous from signing of ICF through Safety Follow-up		All medications taken within 14 days before the Screening Visit through end of the study; Section 9.5 .
Treatment and procedures review	Continuous from signing of ICF through Safety Follow-up		
Adverse events	Continuous from signing of ICF through Safety Follow-up		Section 11.5.1

β-hCG: beta-human chorionic gonadotropin; BMI: body mass index; CRU: clinical research unit; FSH: follicle-stimulating hormone; HBsAg: hepatitis B surface antigen; HCV Ab: hepatitis C virus antibody; HIV-1/HIV-2 Abs: antibodies against human immunodeficiency viruses 1 and 2; ICF: informed consent form; PE: physical examination; PK: pharmacokinetics

^a When assessment time points coincide, assessments will be performed in this order: vital signs, 12-lead ECG, PE, and blood sample collection.

Table 3-2 Study VX21-548-102: Procedure Through Randomization

Event/Assessment	Day 1	Comments
	Procedure Through Randomization / Predose ^a	
Inpatient CRU	X	
Abdominoplasty	X	Section 9.1
Fasting period	X	No food or drink (except water) from time of surgery completion through 4 hours after the first dose of study drug; Section 9.4.2 .
Record supplemental analgesia medication	X	Record pain medications given postoperatively through time subject is randomized. Refer to Section 9.4.1.1 for permitted pain medication.
Vital signs	X	Perform after surgery completion (at least 1 hour after surgery completion is recommended unless the subject requests study drug within 1 hour) and before the first dose of study drug. Complete after a ≥ 5 -minute rest and before blood draws or ECG assessments. Section 11.5.3 .
Standard 12-lead ECG	X	Perform after surgery completion (at least 1 hour after surgery completion is recommended unless the subject requests study drug within 1 hour) and before the first dose of study drug. Complete after a ≥ 5 -minute rest in the supine position and before blood draws or any procedures that may affect heart rate. Section 11.5.4 .
VRS at rest	X	Complete upon request for the first dose of study drug for pain relief after surgery completion. Pain intensity will be recorded after a ≥ 3 -minute rest in bed in either the supine or up to approximately 15-degree head-up position; Section 11.3 .
NPRS at rest	X	Complete immediately after VRS at rest only if pain is rated moderate or severe on VRS at rest. Pain intensity will be recorded after a ≥ 3 -minute rest in bed in either the supine or up to approximately 15-degree head-up position; Section 11.4.2 .
Randomization	X	Subject must request study drug for relief of pain meeting criteria (≥ 4 on NPRS at rest and moderate or severe on VRS at rest) within 4 hours after surgery completion to be eligible for randomization (Section 8.1).
Medications review	Continuous from signing of ICF through Safety Follow-up	All medications taken within 14 days before the Screening Visit through end of the study; Section 9.5 .
Treatment and procedures review	Continuous from signing of ICF through Safety Follow-up	
Adverse events	Continuous from signing of ICF through Safety Follow-up	Section 11.5.1

CRU: clinical research unit; ICF: informed consent form; NPRS: Numeric Pain Rating Scale; VRS: Verbal Categorical Rating Scale

^a Subject must complete all Day 1 predose assessments before the first dose of study drug is administered.

Table 3-3 Study VX21-548-102: Treatment Period and Safety Follow-up

Event/ Assessment ^a	Hours After First Dose																	SFU ^b	Comments		
	0 ^c	0.5	1	1.5	2	3	4	5	6	8	12	16	18	20	24	25 to 32	35 to 44			48	
Inpatient CRU	Continuous from admission through completion of 48-hour assessments																				
Discharge from CRU																			X	Upon completion of all study assessments.	
Outpatient Visit																			X	Section 9.1.4	
PGA of study drug																			X	Complete before the start of any other assessments scheduled at the same time point; Section 11.3.2	
Vital signs					X		X								X				X	X	Complete after ≥5-minute rest (Section 11.5.3). Acceptable window is ± 1 hour from the scheduled time point.
Standard 12-lead ECG							X					X				28 h	40 h				Complete after ≥5-minute rest in the supine position. ECGs must be performed before blood draws or any procedures that may affect heart rate (Section 11.5.4). Acceptable window is ± 1 hour from the scheduled time point.
Complete PE																			X	X	Section 11.5.3
Focused PE																			X	X	Assess wound healing at the operative site; Section 11.5.3 .
NPRS at rest		X	X	X	X	X	X	X	X	X	X	X		X	X	28 h 32 h	36 h 40 h 44 h	X			Pain intensity will be recorded after a ≥3-minute rest in bed in either the supine or up to approximately 15-degree head-up position. Acceptable window is ± 5 minutes from the scheduled time point; Section 11.4.2 .
NPRS during movement									X	X	X		X	X	28 h 32 h	36 h 40 h 44 h	X			Perform immediately after completion of NPRS at rest. Pain intensity will be recorded after the subject sits up in bed, unassisted, at an angle of approximately 45 degrees or more; Section 11.4.2 .	
DNA blood sample (optional)	X																		May be collected anytime during CRU confinement after randomization; Section 11.3.3 .		
Blood sampling for PK			X		X		X	X	X						X	25, 26, 28, 30, and 32 h	36 h	X			At 12, 24, and 36 hours after first dose: Collect within 15 minutes before the next study drug dose. At all other time points after first dose: Collect within ± 30 minutes of scheduled time point. Section 11.2.1 .
Serum chemistry																			X		Section 11.5.2
Hematology																			X		Section 11.5.2
Coagulation																			X		Section 11.5.2 11.5.2
Urinalysis																			X		Section 11.5.2
Fasting period	0 to 4 h					11 to 15 h					23 to 27 h					35 to 39 h		No food or drink (except water); Section 9.4.2 .			
Study drug administration	X							X		X		X		X	30 h	36 h 42 h					To maintain the blind, all subjects receive the same number of tablets and/or capsules q6h; Section 9.6 .

^a When assessment time points coincide, assessments will be performed in this order: PGA of study drug, vital signs, 12-lead ECG, PE, NPRS at rest, NPRS during movement, and blood sample collection. Assessments that coincide with study drug administration will be performed before dosing unless noted otherwise.

^b Safety Follow-up Visit is 14 ± 2 days after the last dose of study drug.

^c Time 0 hours is defined as the first dose of study drug. The first dose of study drug should be administered immediately after completion of all Day 1 predose assessments ([Table 3-2](#)).

Table 3-3 Study VX21-548-102: Treatment Period and Safety Follow-up

Event/ Assessment ^a	Hours After First Dose																	SFU ^b	Comments
	0 ^c	0.5	1	1.5	2	3	4	5	6	8	12	16	18	20	24	25 to 32	35 to 44		
Double-stopwatch	X																		At the time of first dose, 2 stopwatches will be started by the appropriate study site staff and given to the subject. The subject will stop the first watch when/if they feel the “first perceptible pain relief” and stop the second watch when/if they feel “meaningful pain relief”. Section 11.4.3 .
Rescue medication use	Ibuprofen 400 mg orally q6h prn (upon request) after first dose of study drug																		Record NPRS at rest immediately before each administration. Record date and time of administration. Sections 9.4.1.2 and 11.4.4 .
Adverse events	Continuous from signing of ICF through Safety Follow-up																		Section 11.5.1
Medications review	Continuous from signing of ICF through Safety Follow-up																		All medications taken within 14 days before the Screening Visit through the end of the study; Section 9.5 .
Treatment and procedures review	Continuous from signing of ICF through Safety Follow-up																		

CRU: clinical research unit; ICF: informed consent form; NPRS: Numeric Pain Rating Scale; PE: physical examination; PGA: Patient Global Assessment; PK: pharmacokinetic; prn: as needed; q6h: every 6 hours; SFU: Safety Follow-up

4 TABLE OF CONTENTS

1	Title Page	1
	Summary of Changes to the Protocol.....	2
2	Protocol Synopsis	3
3	Schedule of Assessments	6
4	Table of Contents	11
	List of Tables.....	14
	List of Figures	14
	List of Abbreviations.....	15
	Abbreviation of Study Numbers	16
5	Introduction	17
	5.1 Background.....	17
	5.2 Study Rationale	17
6	Study Objectives	18
	6.1 Primary Objective.....	18
	6.2 Secondary Objective.....	18
	6.3 Other Objective	18
7	Study Endpoints	18
	7.1 Primary Endpoint.....	18
	7.2 Secondary Endpoints	18
	7.3 Other Endpoints	18
8	Study Population	18
	8.1 Inclusion Criteria	19
	8.2 Exclusion Criteria.....	19
9	Study Implementation	21
	9.1 Study Design	21
	9.1.1 Screening	23
	9.1.1.1 Repetition of Screening Assessments	23
	9.1.1.2 Rescreening.....	23
	9.1.2 Abdominoplasty Procedure to Randomization.....	23
	9.1.3 Treatment Period	24
	9.1.4 Follow-up.....	24
	9.1.5 Early Discontinuation	24
	9.2 Method of Assigning Subjects to Treatment Groups	24
	9.3 Rationale for Study Elements	24
	9.3.1 Study Design.....	24
	9.3.2 Study Drug Dose and Duration	25
	9.3.3 Rationale for Study Assessments	25
	9.4 Study Restrictions.....	26
	9.4.1 Analgesic Medications	27
	9.4.1.1 Perioperative Pain Management	27
	9.4.1.2 Rescue Medication.....	28
	9.4.2 Additional Dietary Restrictions	28
	9.5 Prior and Concomitant Medications	28
	9.6 Administration.....	29

9.7	Dose Modification for Toxicity.....	29
9.8	Removal of Subjects.....	29
9.9	Replacement of Subjects	30
10	Study Drug Information and Management.....	30
10.1	Preparation and Dispensing.....	30
10.2	Packaging and Labeling	30
10.3	Study Drug Supply, Storage, and Handling	30
10.4	Drug Accountability	31
10.5	Disposal, Return, or Retention of Unused Drug.....	31
10.6	Compliance.....	31
10.7	Blinding and Unblinding	31
10.7.1	Blinding	31
10.7.2	Unblinding.....	32
11	Assessments	33
11.1	Subject and Disease Characteristics	33
11.2	Pharmacokinetics.....	33
11.2.1	Blood Sampling.....	33
11.2.2	Processing and Handling of Pharmacokinetic Samples	33
11.2.3	Bioanalysis.....	33
11.3	Other Assessments.....	34
11.3.1	Verbal Categorical Rating Scale.....	34
11.3.2	Patient Global Assessment of Study Drug	34
11.3.3	Exploratory Assessments: Pharmacogenomics	34
11.4	Efficacy.....	34
11.4.1	Placebo and Pain Assessment Video Training	34
11.4.2	Numeric Pain Rating Scale.....	34
11.4.3	Double-stopwatch Assessment.....	35
11.4.4	Use of Rescue Medications	35
11.5	Safety.....	35
11.5.1	Adverse Events.....	35
11.5.2	Clinical Laboratory Assessments	35
11.5.3	Physical Examinations and Vital Signs	37
11.5.4	Electrocardiograms.....	37
11.5.5	Contraception and Pregnancy.....	38
11.5.5.1	Contraception.....	38
11.5.5.2	Pregnancy.....	40
12	Statistical Analysis.....	40
12.1	Sample Size and Power	40
12.2	Analysis Sets	41
12.3	Statistical Analysis	41
12.3.1	General Considerations.....	41
12.3.2	Background Characteristics.....	41
12.3.3	Efficacy Analysis.....	42
12.3.3.1	Analysis of Primary Endpoint.....	42
12.3.3.2	Analysis of Secondary Efficacy Endpoints.....	42
12.3.3.3	Multiplicity Adjustment.....	42

12.3.3.4	Missing Data Handling	42
12.3.4	Safety Analysis	42
12.4	Interim Analysis	43
12.5	Data Monitoring Committee Analysis.....	43
12.6	Clinical Pharmacology Analysis	43
12.6.1	Pharmacokinetic Analysis	43
12.6.2	Pharmacokinetic/Pharmacodynamic Analyses.....	43
13	Procedural, Ethical, Regulatory, and Administrative Considerations	43
13.1	Adverse Event and Serious Adverse Event Documentation, Severity Grading, and Reporting	43
13.1.1	Adverse Events	43
13.1.1.1	Definition of an Adverse Event.....	43
13.1.1.2	Clinically Significant Assessments	43
13.1.1.3	Documentation of Adverse Events.....	44
13.1.1.4	Adverse Event Severity.....	44
13.1.1.5	Adverse Event Causality	45
13.1.1.6	Study Drug Action Taken	45
13.1.1.7	Adverse Event Outcome	46
13.1.1.8	Treatment Given.....	46
13.1.2	Serious Adverse Events	46
13.1.2.1	Definition of a Serious Adverse Event.....	46
13.1.2.2	Reporting and Documentation of Serious Adverse Events.....	47
13.1.2.3	Expedited Reporting and Investigator Safety Letters	48
13.2	Administrative Requirements	48
13.2.1	Product Complaints	48
13.2.2	Ethical Considerations	48
13.2.3	Subject Information and Informed Consent	48
13.2.4	Investigator Compliance.....	48
13.2.5	Access to Records.....	49
13.2.6	Subject Privacy	49
13.2.7	Record Retention	49
13.2.8	Study Termination	49
13.2.9	End of Study	50
13.3	Data Quality Assurance	50
13.4	Monitoring.....	50
13.5	Electronic Data Capture	50
13.6	Confidentiality and Disclosure	51
13.7	Publications and Clinical Study Report.....	51
13.7.1	Publication of Study Results.....	51
13.7.2	Clinical Study Report	52
14	References.....	53
15	Protocol Signature Pages	56
15.1	Sponsor Signature Page.....	56
15.2	Investigator Signature Page	57

List of Tables

Table 2-1	VX21-548-102 Treatment Groups.....	5
Table 3-1	Study VX21-548-102: Screening Through Admission.....	7
Table 3-2	Study VX21-548-102: Procedure Through Randomization.....	8
Table 3-3	Study VX21-548-102: Treatment Period and Safety Follow-up.....	9
Table 9-1	VX21-548-102 Treatment Groups.....	22
Table 9-2	Study Restrictions.....	27
Table 10-1	Study Drug.....	30
Table 11-1	Acceptable Pharmacokinetic Sampling Windows.....	33
Table 11-2	Safety Laboratory Test Panels.....	36
Table 11-3	Contraceptive Requirements.....	39
Table 13-1	Grading of AE Severity.....	45
Table 13-2	Classifications for AE Causality.....	45
Table 13-3	Classifications for Study Drug Action Taken With Regard to an AE.....	46
Table 13-4	Classifications for Outcome of an AE.....	46

List of Figures

Figure 2-1	VX21-548-102 Study Design.....	4
Figure 9-1	VX21-548-102 Study Design.....	22

List of Abbreviations

Abbreviation	Definition
ADL	activities of daily living
AE	adverse event
AMSAP	abbreviated modeling and simulation analysis plan
ANCOVA	analysis of covariance
AUC ₀₋₂₄	area under the concentration versus time curve from the time of dosing to 24 hours
β-hCG	beta-human chorionic gonadotropin
BMI	body mass index
CI	confidence interval
C _{max}	maximum observed concentration
CPAP	clinical pharmacology analysis plan
CRF	case report form
CRO	contract research organization
CRU	clinical research unit
CSR	clinical study report
CTCAE	Common Terminology Criteria for Adverse Events
CYP	cytochrome P450
DNA	deoxyribonucleic acid
DRG	dorsal root ganglia
ECG	electrocardiogram
EDC	electronic data capture
FAS	Full Analysis Set
FDA	Food and Drug Administration
FSH	follicle-stimulating hormone
GCP	Good Clinical Practice
GLP	Good Laboratory Practice
GPS	Global Patient Safety
h	hour
HB/APAP	hydrocodone bitartrate/acetaminophen
HBsAg	hepatitis B surface antigen
HCV Ab	hepatitis C virus antibody
HIPAA	Health Insurance Portability and Accountability Act
HIV-1/HIV-2 Abs	antibodies against human immunodeficiency viruses 1 and 2
ICF	informed consent form
ICH	International Council for Harmonization
IEC	independent ethics committee
IMP	investigational medicinal product
IND	Investigational New Drug (application) (US)
IRB	institutional review board
IV	intravenous
IXRS	interactive response system in which X represents voice or web, such as IWRS
max	maximum value
min	minimum value
n	size of subsample
Nav	voltage-gated sodium channel
NOAEL	no-observed-adverse-effect-level

Abbreviation	Definition
NPRS	Numeric Pain Rating Scale
NSAIDs	nonsteroidal anti-inflammatory drugs
<i>P</i>	probability
PE	physical examination
PGA	Patient Global Assessment
PK	pharmacokinetic, pharmacokinetics
prn	as needed
q6h	every 6 hours
q12h	every 12 hours
q24h	every 24 hours
QTcF	QT interval corrected by Fridericia's formula
SAE	serious adverse event
SAP	statistical analysis plan
SD	standard deviation
SET	Study Execution Team
SFU	Safety Follow-up
SPID	sum of the pain intensity difference
SPID _{m8-24}	sum of the pain intensity difference during movement from 8 to 24 hours
SPID _{m8-48}	sum of the pain intensity difference during movement from 8 to 48 hours
SPID _{r0-24}	sum of the pain intensity difference at rest from 0 to 24 hours
SPID _{r0-48}	sum of the pain intensity difference at rest from 0 to 48 hours
TE	treatment-emergent
TEAE	treatment-emergent adverse event
US	United States
VRS	Verbal Categorical Rating Scale

Abbreviation of Study Numbers

Abbreviation	Study Number
Study 001	Study VX19-548-001
Study 002	Study VX20-548-002

5 INTRODUCTION

5.1 Background

Pain is one of the most common symptoms for which patients seek medical attention. Current treatment options for pain are limited by poor efficacy and high rates of adverse events (AEs), leaving many patients without adequate pain control. Nonsteroidal anti-inflammatory drugs (NSAIDs) pose a potentially serious risk of gastrointestinal toxicity with acute and chronic use, hematologic toxicity with acute use, and nephrotoxicity with chronic use.¹ Opioids, commonly prescribed for moderate-to-severe pain, are significantly limited by safety and tolerability issues and have a high abuse liability. Opioid-associated deaths have increased in frequency over the past 2 decades.² More than 50,000 deaths attributable to opioids occurred in the US from 2019 to 2020, and more than 80% of fatal drug overdoses in Europe involved opioids.^{3,4}

Given the limited treatment options, combined with the risks and relative ineffectiveness of current treatments, the development of new analgesics with improved efficacy and safety profiles is vital for better patient management and health outcomes. Despite the need for new analgesics, clinical development has exhibited a considerable lack of recent progress and innovation of new medications to treat pain. The majority of analgesic drugs approved over the last decade either act on the opioid receptor system or are NSAIDs⁵; only 3 new molecular entity drugs for moderate to severe pain have been approved by the FDA since 2008.⁶⁻¹⁰ The majority of research activity focuses on developing abuse-deterrent reformulations of existing narcotic pain drugs; however, these drugs do not substantially improve efficacy or safety.

Voltage-gated sodium channel 1.8 (Nav1.8) plays a critical role in pain signaling.^{11,12} Support for this assertion arises from (1) evaluation of the role Nav1.8 plays in normal physiology¹³⁻¹⁷, (2) pathological states arising from mutations in the Nav1.8 gene (*SCN10A*)^{18,19}, (3) animal models²⁰⁻²³, and (4) pharmacology of known Nav1.8-modulating agents.²⁴⁻²⁶ In addition, because Nav1.8 expression is restricted to peripheral neurons, particularly those that sense pain (e.g., the dorsal root ganglia [DRG])^{13,15}, Nav1.8 inhibitors are less likely to be associated with the side effects commonly observed with other sodium channel modulators and the abuse liability associated with opioid therapies. Therefore, targeting the underlying biology of pain through selective Nav1.8 inhibition represents a novel approach to analgesic drug development that has the potential to address an urgent unmet need for safe and effective acute and chronic pain therapies. These therapies include treatment where the primary mechanisms underlying pain are nociceptor hyperexcitability.

VX-548 is being developed for the treatment of pain. VX-548 is a Nav1.8 inhibitor that is highly selective for Nav1.8 relative to other Nav channels. Refer to the VX-548 Investigator's Brochure for additional details.²⁷

5.2 Study Rationale

Clinical data from 2 Phase 1 studies evaluating single and multiple ascending doses of VX-548 demonstrated that VX-548 is generally safe and well tolerated in healthy subjects (Studies 001 and 002).²⁷

This study will evaluate the efficacy and safety of 2 VX-548 doses in treating acute pain after an abminoplasty.

6 STUDY OBJECTIVES

6.1 Primary Objective

- To evaluate the efficacy of VX-548 doses in treating acute pain after an abdominoplasty

6.2 Secondary Objective

- To evaluate the safety and tolerability of VX-548

6.3 Other Objective

- To evaluate the pharmacokinetics (PK) of VX-548 and its metabolite, [REDACTED]

7 STUDY ENDPOINTS

7.1 Primary Endpoint

- Time-weighted sum of the pain intensity difference (SPID) as recorded on a Numeric Pain Rating Scale (NPRS) at rest 0 to 48 hours (SPID_{r0-48}) after the first dose of study drug

7.2 Secondary Endpoints

- Time-weighted SPID as recorded on an NPRS at rest 0 to 24 hours (SPID_{r0-24}) after the first dose of study drug
- Proportions of subjects with $\geq 30\%$, $\geq 50\%$, and $\geq 70\%$ reduction in NPRS at rest at 48 hours after the first dose of study drug
- Safety and tolerability based on the incidence and type of AEs, changes from baseline in clinically significant laboratory test results, vital signs, and ECGs

7.3 Other Endpoints

- Time-weighted SPID as recorded on an NPRS during movement 8 to 24 hours (SPID_{m8-24}) and 8 to 48 hours (SPID_{m8-48}) after the first dose of study drug
- Time to onset of “confirmed perceptible pain relief” and “meaningful pain relief” after the first dose of study drug
- Proportions of subjects with $\geq 30\%$, $\geq 50\%$, and $\geq 70\%$ reduction in NPRS at rest at 24 hours after the first dose of study drug
- Patient Global Assessment (PGA) of study drug at 48 hours after the first dose of study drug
- Percentage of subjects using rescue medication, and total rescue medication usage, 0 to 48 hours after the first dose of study drug
- PK parameter estimates of VX-548 and its metabolite, [REDACTED]

8 STUDY POPULATION

Eligibility will be reviewed and documented by an appropriately qualified member of the investigator’s team before subjects are enrolled.

Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be eligible.

8.1 Inclusion Criteria

Before Surgery:

1. Subject will sign and date an informed consent form (ICF).
2. Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures.
3. Subjects (male or female) between the ages of 18 and 75 years, inclusive.
4. Body mass index (BMI) of 18.0 to 38.0 kg/m², inclusive.
5. Subject scheduled to undergo a standard (“full”) abdominoplasty procedure that:
 - o includes a horizontally oriented incision approximately extending to (but not exceeding) each anterior superior iliac spine;
 - o includes umbilical dissection and relocation, and plication of the fascia of the rectus muscle above and/or below the umbilical stalk;
 - o does NOT include a vertically oriented supra-umbilical incision or collateral procedures (e.g., liposuction); and
 - o can include drain placement and skin closure at the discretion of the surgeon

After Surgery:

6. Subject reported pain of ≥ 4 on the NPRS at rest and moderate or severe pain on the Verbal Categorical Rating Scale (VRS) at rest within 4 hours after surgery completion on Day 1.
7. Subject is lucid, able to follow commands, and able to swallow oral medications.
8. All analgesic guidelines ([Section 9.4.1](#)) were followed during and after the abdominoplasty.
9. Abdominoplasty procedure duration ≤ 3 hours.

8.2 Exclusion Criteria

Before Surgery:

1. Prior history of abdominoplasty.
2. History of intra-abdominal and/or pelvic surgery (including hysterectomy and Cesarean section) that resulted in any complications (e.g., postoperative infections, incisional infections or dehiscence, wound infections, or re-exploration/redo surgery for the same condition) or, in the opinion of the investigator or medical monitor, would preclude participation in the study.
3. History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to, history of relevant drug or food allergies; history of significant respiratory, renal, hepatic, cardiovascular, metabolic, neurologic, or psychiatric disease; history or presence of clinically significant pathology; and history of cancer, except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ (all 3 with no recurrence for the last 5 years).

4. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s); or history or evidence of abnormal study ECGs that in the opinion of the investigator or medical monitor would preclude the subject's participation in the study.
5. Alanine aminotransferase or aspartate aminotransferase values $>2.5 \times$ upper limit of normal.
6. Any other abnormal laboratory results indicative of significant medical disease that, in the opinion of the investigator, would preclude the subject's participation in the study.
7. History of any sensory abnormality that, in the opinion of the investigator, may confound the ability of the subject to assess postoperative pain.
8. Subjects who have a painful physical condition that, in the opinion of the investigator, may confound the assessments of postoperative pain.
9. A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses.
10. Any prior surgery within 1 month before the first study drug dose unless approved by the medical monitor.
11. American Society of Anesthesiologists physical status classification of ≥ 3 .
12. Chronic use of opioids or NSAIDs with dose escalation within 30 days before admission and/or unwilling or unable to stop analgesics at least 5 half-lives or 2 days (whichever is longer) before admission.
13. Subjects who have started new medications that have not been at a stable dose for at least 14 days prior to the scheduled abdominoplasty procedure and before dosing with investigational product.
14. Subjects unwilling to receive any protocol-related medicine (e.g., ibuprofen, acetaminophen, fentanyl, hydrocodone).
15. Subjects with a history of allergy or significant AE to any opioid and/or NSAID that, in the opinion of the investigator, would significantly increase the chance of AEs from medicines used in the study.
16. Subjects with sleep apnea and/or on a home continuous positive airway pressure machine.
17. History of peptic ulcer disease or gastrointestinal bleeding that, in the opinion of the investigator or medical monitor, would preclude the subject's participation in the study.
18. For female subjects: Pregnant, nursing, or planning to become pregnant during the study or within 30 days after the last study drug dose.
For male subjects: Male subjects with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 30 days after the last study drug dose.
19. Participation in a previous study investigating VX-548.
20. Participated in another investigational study within 30 days of the first dose of study drug.
21. Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse in the past 3 years, or a positive test for drugs of abuse as defined in [Section 11.5.2](#).

- o A positive drug screen for a known prescribed concomitant medication that is not otherwise exclusionary (e.g., benzodiazepines) will not disqualify subjects; however, marijuana (or any cannabis derivative) will not be allowed.
22. Use of the substances, activities, or devices, as defined in [Section 9.4](#), during the specified times.
 23. Subject, or close relative of the subject, is the investigator or a sub-investigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site.

After Surgery:

24. Subject had medical complications during the abdominoplasty that, in the opinion of the investigator, should preclude randomization.
25. Subject had a non-standard abdominoplasty and/or collateral procedures during the abdominoplasty.


9 STUDY IMPLEMENTATION**9.1 Study Design**

This is a Phase 2, randomized, double-blind, placebo-controlled, 4-arm, parallel study design evaluating the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty ([Figure 9-1](#)).

On Day 1, subjects will undergo a standard (“full”) abdominoplasty procedure (as defined in [Section 8.1](#)). After surgery completion, a subject will be randomized to 1 of 4 treatment groups if (1) the subject requests the first dose of study drug for pain relief, (2) the subject’s pain is moderate or severe on the VRS at rest, and (3) the subject’s pain is ≥ 4 on the NPRS at rest. If a subject does not meet the VRS and NPRS criteria within 4 hours of surgery completion, the subject will not be eligible for this study.

Approximately 256 subjects will be randomized 1:1:1:1 to 4 treatment groups: high-dose VX-548 (100 mg/50 mg every 12 hours [q12h]); low-dose VX-548 (60 mg/30 mg q12h); hydrocodone bitartrate/acetaminophen (HB/APAP; opioid reference); or placebo (-1). Randomization will be stratified by site and baseline NPRS at rest (< 8 versus ≥ 8). To maintain the blind, all subjects will receive the same number of tablets and/or capsules every 6 hours (q6h) in a double-dummy design.

Figure 9-1 VX21-548-102 Study Design



CRU: clinical research unit; HB/APAP: hydrocodone bitartrate/acetaminophen; NPRS: Numeric Pain Rating Scale; VRS: Verbal Categorical Rating Scale

Notes: After surgery completion, a subject will be randomized to 1 of 4 treatment groups if (1) the subject requests the first dose of study drug for pain relief, (2) the subject’s pain is moderate or severe on the VRS at rest, and (3) the subject’s pain is ≥ 4 on the NPRS at rest. If a subject does not meet the VRS and NPRS criteria within 4 hours of surgery completion, the subject will not be eligible for this study.

Table 9-1 VX21-548-102 Treatment Groups

Treatment	Active Dose	Number of Subjects
VX-548 (high dose)	100 mg first dose, then 50 mg q12h	64
VX-548 (low dose)	60 mg first dose, then 30 mg q12h	64
HB/APAP	5 mg/325 mg q6h	64
Placebo		64

HB/APAP: hydrocodone bitartrate/acetaminophen; q6h: every 6 hours; q12h: every 12 hours

Note: To maintain the blind, all subjects will receive the same number of tablets and/or capsules q6h in a double-dummy design. VX-548 active and/or VX-548 placebo will be administered to all subjects q12h: 0 hours (first dose) and at 12, 24 and 36 hours after the first dose of study drug. HB/APAP active or HB/APAP placebo will be administered to all subjects q6h: 0 hours (first dose) and at 6, 12, 18, 24, 30, 36 and 42 hours after the first dose of study drug.

Subjects will report their pain intensity on the NPRS at rest at each scheduled time point through 48 hours after the first dose of study drug. Starting 8 hours after the first dose of study drug, subjects will also report their pain intensity on the NPRS during movement. In addition, pain intensity will be recorded on the NPRS at rest immediately before each administration of rescue medication (Section 9.4.1.2).

Ibuprofen (400 mg orally q6h as needed [prn]) is permitted as a rescue medication for pain relief upon the subject’s request starting any time after the first dose of study drug through 48 hours after the first dose of study drug. Subjects are encouraged to wait 90 minutes after the first dose of study drug to request rescue medication, and subjects should generally not receive rescue medication unless their NPRS at rest score is ≥ 4 .

9.1.1 Screening

Screening assessments are listed in [Table 3-1](#). Screening includes Screening Visit assessments required before the day of surgery and pre-procedure assessments required on the day of surgery.

The Screening Visit will occur within 28 days before the scheduled abdominoplasty procedure. The investigator (or an appropriate authorized designee at the study site) will obtain informed consent from each subject.

To prepare for study participation, subjects will be instructed on the study restrictions ([Section 9.4](#)).

9.1.1.1 Repetition of Screening Assessments

Repetition of any screening assessment that did not meet eligibility criteria is not permitted, unless there is clear evidence of a laboratory error (e.g., hemolysis of sample, equipment error).

9.1.1.2 Rescreening

Subjects who do not meet the eligibility criteria may not be rescreened, with the following exceptions:

- Subjects who met all eligibility criteria but had an intercurrent illness (e.g., upper respiratory infection with fever) in the 5 days before the first dose of study drug that was properly evaluated and which resolved fully
- Subjects who met all eligibility criteria but were not able to obtain required documentation within the allotted screening window
- Subjects who met all eligibility criteria but transiently (for personal reasons) are unable to commit to all study procedures
- Subjects who were screened under a prior version of the protocol and did not meet any exclusion criterion, with the exception of a criterion that was updated in a subsequent version of the protocol

Any subject who is rescreened for any of the exceptions listed above may have the screening window extended by 1 week before needing to undergo any rescreening assessments. If more than 35 days have elapsed from the Screening Visit before first dose of study drug, all screening assessments need to be repeated.

9.1.2 Abdominoplasty Procedure to Randomization

Assessments to be completed after the abdominoplasty procedure through randomization are listed in [Table 3-2](#).

Subjects will receive 4 mg of intravenous (IV) ondansetron once at the beginning of surgery. After surgery, subjects may receive 4 mg of IV ondansetron every 8 hours prn for nausea and/or vomiting. Refer to [Section 9.4.1.1](#) for details on perioperative pain management.

All study periods will be conducted as described in [Section 9.1](#). If a subject does not meet the VRS and NPRS criteria ([Section 8.1](#)) within 4 hours of surgery completion, the subject will not be eligible for this study.

9.1.3 Treatment Period

Treatment Period assessments are listed in [Table 3-3](#).

All study periods will be conducted as described in [Section 9.1](#). Dosing details are in [Section 9.6](#).

If a subject has any clinically significant, study-related abnormalities at the conclusion of the scheduled inpatient portion of the study, the medical monitor (or authorized designee) will be notified, and the subject will be asked to remain in the clinical research unit (CRU) until such abnormalities resolve. If the subject is unable or unwilling to remain in the CRU, the medical monitor (or authorized designee) will be notified, and the investigator will make every effort to arrange follow-up evaluations at appropriate intervals to document the course of the abnormalities.

9.1.4 Follow-up

Subjects will have an in-person Safety Follow-up Visit 14 (\pm 2) days after the last dose of study drug. Safety Follow-up assessments are listed in [Table 3-3](#).

9.1.5 Early Discontinuation

Subjects who prematurely discontinue study drug dosing will remain under observation for at least 12 hours after the last dose of study drug, after which point they can be discharged from the CRU. If a subject has any clinically significant, study-related abnormalities, the medical monitor (or authorized designee) will be notified, and the subject will be asked to remain in the CRU until such abnormalities resolve. If the subject is unable or unwilling to remain in the CRU, the medical monitor (or authorized designee) will be notified, and the investigator will make every effort to arrange follow-up evaluations at appropriate intervals to document the course of the abnormalities.

Subjects who prematurely discontinue study drug dosing will be required to complete the Safety Follow-up Visit 14 (\pm 2) days after the last dose of study drug.

9.2 Method of Assigning Subjects to Treatment Groups

Approximately 256 subjects will be randomized 1:1:1:1 to 4 treatment groups: VX-548 (high dose); VX-548 (low dose); HB/APAP (opioid reference); or placebo. The randomization ratio of 1:1:1:1 will be controlled for the overall study, and the details of the randomization implementation will be specified in separate documents.

Each randomized subject will be assigned a unique subject number. Randomization will be stratified by site and baseline NPRS at rest (<8 versus ≥ 8).

An interactive web or voice response system (IXRS) will be used to assign subjects to treatment. The randomization code will be produced by Vertex Biostatistics or a qualified randomization vendor. The Vertex study biostatistician will review and approve the production of the final randomization list, which will be reviewed and approved by a designated unblinded biostatistician who is not a member of the Study Execution Team (SET).

9.3 Rationale for Study Elements

9.3.1 Study Design

Abdominoplasty is a well-established, multi-dose, surgical, acute pain model. A randomized, double-blind study design was selected to avoid observer bias and reduce symptoms or outcomes

arising from the subjects' knowledge of treatment. A parallel design is considered most appropriate given the acute nature of abdominoplasty surgery.

Two VX-548 doses will be evaluated to help inform dose selection for Phase 3 studies. An opioid reference group assessing a standard-of-care treatment (HB/APAP 5 mg/325 mg q6h) was included to establish the ability of the study, as executed, to successfully observe a treatment effect.

Following a standard study design, subjects will be randomized after surgery and after the subject's pain meets the pain threshold criteria. The pain threshold criteria are designed to ensure subjects have sufficient pain to determine if the drug is effective. Ibuprofen was selected as the rescue medication because it is a commonly used, short-acting, standard-of-care treatment for acute pain.

9.3.2 Study Drug Dose and Duration

VX-548 doses (-1) were selected based on favorable safety and PK data from healthy volunteers in Study 001 (single ascending dose study) and Study 002 (multiple ascending dose study). Multiple oral doses up to 65 mg administered in solution/suspension every 24 hours (q24h) for 14 days have been evaluated and found to be safe and well tolerated.²⁷ The selected VX-548 doses are predicted to achieve concentrations that are able to produce 87% (60 mg/30 mg q12h) to 91% (100 mg/50 mg q12h) Nav1.8 inhibition in the in vitro human DRG assay.

Based on population PK modeling, the mean exposures (AUC_{0-24} and C_{max}) for VX-548 and its major metabolite, [REDACTED], at the high dose in this study (100 mg/50 mg q12h administered as tablets) are predicted to be within the range of exposures observed at the highest tested dose found to be safe and well tolerated in humans in Study 001 and Study 002 and provide the following safety margins to the no-observed-adverse-effect level (NOAEL) observed in monkey in the 28-day GLP toxicity study:²⁷

- VX-548: 2.8-fold and 3.8-fold below the NOAEL for AUC_{0-24} and C_{max} , respectively
- [REDACTED]: 4.0-fold and 6.3-fold below the NOAEL for AUC_{0-24} and C_{max} , respectively

The population PK model was based on observed PK data for the suspension/solution formulation of VX-548 and adjusted based on the relative bioavailability between the tablet and solution formulations of VX-548.

9.3.3 Rationale for Study Assessments

VRS: A 4-point VRS (none, mild, moderate, or severe) is included as part of the pain threshold inclusion criterion to ensure that all subjects have moderate or severe pain at baseline, which ensures subjects have sufficient pain to determine if the study drug is effective.

NPRS: NPRS is frequently used in abdominoplasty studies and is recognized by the FDA as a valid pain intensity measure.²⁸ Pain rated ≥ 4 on an 11-point (0 to 10) NPRS at baseline ensures subjects have sufficient pain to determine if the study drug is effective.

Pain at rest is the standard outcome measure in postoperative analgesic trials. However, there is evidence that pain during movement, commonly referred to as "movement-evoked pain", may be more sensitive to treatment effects than pain at rest.^{29, 30} Movement-evoked pain is more intense than pain at rest in the first 3 postoperative days,³¹ providing an opportunity to demonstrate differential efficacy among active treatments.^{29, 32}

Double-stopwatch assessment: The double-stopwatch assessment is a standardized assessment for determining the onset of pain relief.^{30, 33} Two stopwatches are started by the appropriate study site staff and given to the subject at the time of the first dose. Subjects are told to stop the first watch when/if they first feel any pain relief (“first perceptible pain relief”) and stop the second watch when/if they first feel pain relief they consider meaningful (“meaningful pain relief”). If a subject achieves “meaningful pain relief”, the time the first watch was stopped is considered the time to “confirmed perceptible pain relief”.

Use of rescue medications: The use of rescue medications is an important covariate in pain studies that can impact the analysis of other efficacy assessments.

PGA of study drug: The PGA of study drug is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 4-point Likert scale (poor, fair, good, or excellent). The PGA of study drug provides subjects the ability to state their perceptions of the treatment that may not be captured by measuring pain intensity alone.

9.4 Study Restrictions

Study restrictions are summarized in [Table 9-2](#). A non-exhaustive list of study restrictions will be provided in the Study Reference Manual.

Table 9-2 Study Restrictions

Restricted Medication/Food/Activity ^a	Timing of Restriction	
	Start	Stop
Other investigational drugs or devices	30 days before first dose of study drug, 5 half-lives before first dose of study drug, or time determined by local requirements (whichever is longer)	Completion of SFU assessments
Analgesic medications (per guidelines in Section 9.4.1)	5 half-lives or 2 days (whichever is longer) before admission to the CRU	Until discharge from CRU
Oral steroids	5 half-lives or 2 days (whichever is longer) before admission to the CRU	Until discharge from CRU
Medications, herbal and dietary supplements (including St. John's wort) known to be moderate or strong inducers of CYP3A	14 days before first dose of study drug	Completion of SFU assessments
Medications, herbal and dietary supplements known to be moderate or strong inhibitors of CYP3A	7 days before first dose of study drug	Completion of SFU assessments
Grapefruit or grapefruit juice, pomelos, star fruit, Seville oranges and their juices, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), and charbroiled meats	7 days before first dose of study drug	Completion of SFU assessments
Alcohol	24 hours before first dose of study drug	Until discharge from CRU
Strenuous exercise (e.g., heavy lifting, weight training, and aerobics)	48 hours before first clinical laboratory testing	Completion of SFU assessments

CRU: clinical research unit; SFU: Safety Follow-up

^a Refer to the Study Reference Manual for a more complete list of medications prohibited/restricted in the study. See [Section 9.5](#) for guidance on concomitant medications.

9.4.1 Analgesic Medications

Apart from standard-of-care during admission, the following analgesic medications are prohibited for 5 half-lives or 2 days (whichever is longer) before admission through discharge from CRU: opioids (except fentanyl citrate), NSAIDs (except ibuprofen rescue), acetaminophen, ketamine, regional or neuraxial anesthesia, and/or local anesthetic infiltration (except lidocaine during the procedure).

9.4.1.1 Perioperative Pain Management

Pre- and perioperative:

- IV midazolam (≤ 2 mg) and/or fentanyl citrate (≤ 50 μ g) may be used preoperatively.
- IV fentanyl citrate and propofol (doses at the discretion of the anesthesia provider) may be used for anesthesia induction.
- IV general anesthesia with propofol and fentanyl citrate will be used for anesthesia maintenance.

- After completing the rectus plication, the rectus fascia should be infiltrated above and below the umbilicus with 1% lidocaine without epinephrine for a total of approximately 4 mg/kg.
- Total fentanyl citrate from induction through emergence may not exceed 250 µg.
- A record (date and time of administration) will be kept of all standard-of-care pain medication use through surgery completion.

Postoperative:

- Postoperative supplemental analgesia medication is permitted in the postanesthesia care unit per the following guidelines:
 - Fentanyl citrate (12.5 to 25 µg IV prn) can be administered if the subject is: 1) not lucid enough for randomization but deemed to be in severe pain per clinical judgement and/or 2) unable to swallow oral medications.
 - Randomization may not occur until at least 15 minutes after the last administration of supplemental analgesia medication.
- The use of abdominal binders is permitted.
- The use of ice packs is **not** permitted.
- No pain treatments (except the permitted supplemental analgesia medication) are allowed from surgery completion until the first dose of study drug.

Refer to [Section 9.1.2](#) for details on perioperative antiemetics.

9.4.1.2 Rescue Medication

- Ibuprofen (400 mg orally q6h prn) is permitted as a rescue medication for pain relief upon the subject's request starting any time after the first dose of study drug through 48 hours after the first dose of study drug.
- Subjects are encouraged to wait 90 minutes after the first dose of study drug to request rescue medication, and subjects should generally not receive rescue medication unless their NPRS at rest score is ≥ 4 .
- A record (date and time of administration) will be kept of all rescue medication use.
- An unscheduled NPRS at rest will be completed immediately before each administration of rescue medication.

9.4.2 Additional Dietary Restrictions

- Subjects will abstain from all food and drink (except ≤ 8 fluid ounces per hour of water) during the fasting periods indicated in [Table 3-2](#) and [Table 3-3](#).

9.5 Prior and Concomitant Medications

- Subjects will abstain from all concomitant medications as described in the exclusion criteria ([Section 8.2](#)) and study restrictions ([Section 9.4](#)).
- All opioid medications taken within 12 months of the Screening Visit through admission will be recorded with indication, route of administration, and start and stop dates of administration.

- All medications taken from 14 days before the Screening Visit through the end of the study will be recorded with indication, route of administration, and start and stop dates of administration. Concomitant medications administered in-clinic will also be recorded with the time of each administration.
- A female subject of childbearing potential using hormonal contraceptives does not need to stop taking hormonal contraceptives; however, they are not considered an approved form of contraception ([Section 11.5.5.1](#)).

9.6 Administration

Study drug will be administered according to the following guidelines:

- To maintain the blind, all subjects will receive the same number of tablets and/or capsules q6h in a double-dummy design:
 - VX-548 active and/or VX-548 placebo will be administered to all subjects q12h: 0 hours (first dose) and at 12, 24, and 36 hours after the first dose.
 - HB/APAP active or HB/APAP placebo will be administered to all subjects q6h: 0 hours (first dose) and at 6, 12, 18, 24, 30, 36, and 42 hours after the first dose.
- Study drug will be administered orally with approximately 240 mL (8 fluid ounces) of water.
- Subjects will swallow the study drug whole and will not chew it before swallowing.
- The date and time of administration of each dose of study drug will be recorded.
- When assessment time points coincide with study drug administration, study drug will be administered after completing all assessments unless noted otherwise.
- Study drug must be administered following the dietary restrictions outlined in [Table 9-2](#) and [Section 9.4.2](#).

Additional information is provided in the Pharmacy Manual.

9.7 Dose Modification for Toxicity

No dose modifications for toxicity are allowed. If any unacceptable toxicity arises, individual subjects will discontinue dosing ([Section 9.1.5](#)).

9.8 Removal of Subjects

Subjects may withdraw from the study at any time at their own request. Subjects may be withdrawn from study drug treatment at any time at the discretion of the investigator or Vertex for safety, behavior, noncompliance with study procedures, or administrative reasons. A subject who withdraws from study drug treatment will continue to be followed unless the subject withdraws consent.

If a subject does not return for a scheduled visit, reasonable effort will be made to contact the subject. In any circumstance, reasonable effort will be made to document subject outcome. The investigator will inquire about the reason for withdrawal, request that the subject participate in a Safety Follow-up Visit, if applicable (see [Section 9.1.5](#)), and follow up with the subject regarding any unresolved AEs.

If a subject withdraws consent for the study, no further assessments will be performed. Vertex may retain and continue using the study data and samples after the study ends, and may use the samples and information in the development of the study compound, for other drugs and diagnostics, in publications and presentations, and for education purposes. If a subject withdraws from the study, the study data and samples collected will remain part of the study. A subject will not be able to request the withdrawal of his/her information from the study data. A subject may request destruction of the samples collected from him/her during the study as long as those samples can be identified as his/her samples.

9.9 Replacement of Subjects

Subjects who withdraw or are withdrawn for nonsafety reasons during the study drug Treatment Period may be replaced at Vertex's discretion.

10 STUDY DRUG INFORMATION AND MANAGEMENT

10.1 Preparation and Dispensing

Study drug may be dispensed only under the supervision of the investigator or an authorized designee and only for administration to the study subjects.

Study drug will be dispensed at the CRU to blinded individual dosing containers by a qualified pharmacist or designated study site staff, and following national and local laws and regulations.

10.2 Packaging and Labeling

Vertex will supply the 10-mg VX-548 tablets, 5-mg/325-mg HB/APAP capsules, and matching placebos. Study drug labeling will be in compliance with applicable local and national regulations. Additional details about study drug packaging, labeling, and dispensing will be in the Pharmacy Manual.

10.3 Study Drug Supply, Storage, and Handling

The investigator, or an authorized designee (e.g., a licensed pharmacist), will ensure that all investigational product is stored in a secured area, under recommended storage conditions, and in accordance with applicable regulatory requirements. Specifically, study drug will be stored at United States Pharmacopeia controlled room temperature in a securely locked, substantially constructed cabinet or other securely locked, substantially constructed enclosure. Access to study drug will be limited to prevent theft or diversion of the study drug. To ensure adequate records, all study drugs will be accounted for via the drug accountability forms as instructed by Vertex.

Study drug supply details are listed in Table 10-1. Detailed instructions regarding the storage, handling, and dispensation of the study drug will be provided in the Pharmacy Manual.

Table 10-1 Study Drug

Drug Name	Dosing Form	Route	How Supplied
VX-548	Tablet	Oral	Supplied as 10-mg tablets
VX-548 placebo	Tablet	Oral	Supplied as tablets
HB/APAP	Capsule	Oral	Supplied as over-encapsulated 5-mg/325-mg tablets
HB/APAP placebo	Capsule	Oral	Supplied as capsules
HB/APAP: hydrocodone bitartrate/acetaminophen			

10.4 Drug Accountability

The pharmacist or designated study site staff will maintain information about the dates and amounts of (1) study drug received and (2) study drug dispensed to the subjects. These materials will be retained at the site according to instructions provided by Vertex or its designee. The study monitor will review study drug records and inventory throughout the study. If a site uses a site-specific drug accountability system and/or process, including processes associated with the destruction of returned materials, the process must be documented and approved by Vertex. The study monitor must review the drug accountability documentation on a regular basis. The study monitor will promptly communicate to Vertex any discrepancies he/she is unable to resolve with the site.

10.5 Disposal, Return, or Retention of Unused Drug

The study site staff or pharmacy personnel will retain all materials until the study monitor has performed drug accountability. The investigator will ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by Vertex. Destruction will be adequately documented.

The principal investigator, study site staff, including pharmacy personnel will assist Vertex with any recall activities (as applicable) and place impacted investigational medicinal product (IMP) in quarantine when requested.

10.6 Compliance

Study drug doses will be administered under the direct supervision of the investigator or designee. A hand-and-mouth check will be done after each dose administration in the CRU to ensure 100% study treatment compliance.

10.7 Blinding and Unblinding

This is a double-blind study.

10.7.1 Blinding

All study personnel will be blinded to subject treatment assignments except for the following individuals:

- Any site personnel for whom this information is important to ensure the safety of a subject in the event of a life-threatening medical emergency
- Any site personnel for whom this information is important to ensure the safety of a subject and a fetus in the event of a pregnancy
- The unblinded site monitor and unblinded trip report reviewer
- Vertex Global Patient Safety (GPS) and Regulatory Affairs personnel to satisfy serious adverse event (SAE) processing and reporting regulations
- External vendor (unblinded) statistician preparing the final (production) randomization list who is not part of the study team
- Vertex IXRS Management for IXRS oversight and system administration
- Vertex Clinical Supply Chain

- The bioanalytical laboratory/vendor personnel responsible for the sample testing (Vertex or external)
- The Vertex bioanalytical personnel responsible for reviewing raw data from the bioanalytical contract research organization (CRO), who is not a member of the SET (the Vertex bioanalytical SET member will continue to be blinded)

Vertex medical monitor may, for matters relating to safety, unblind individual subjects at any time.

A limited Vertex team not directly involved in the conduct of the study may be unblinded to individual subject treatment assignments and have access to PK, efficacy, and/or safety data (e.g., AEs, clinical laboratory assessments) for continuous monitoring purposes. These individuals will not be a member of the study team and will not interact with the CRU or study personnel. No unblinded data or results of unblinded analyses will be shared with the CRU or with blinded Vertex personnel. Masked identifications will be used for PK and efficacy analyses. All instances of unblinding by Vertex personnel will be documented.

10.7.2 Unblinding

At the initiation of the study, study site personnel will be instructed on the method for breaking the blind. The unblinding method will be either manual or electronic.

Unblinding of the individual subject's treatment by the investigator will be limited to medical emergencies or urgent clinical situations in which knowledge of the subject's study treatment is necessary for clinical management. In such cases, investigators will use their best judgment as to whether to unblind without first attempting to contact the medical monitor to discuss unblinding. If investigators deem it unnecessary to unblind immediately, they will first attempt to contact the medical monitor to discuss unblinding. If investigators have tried but are unable to reach the medical monitor, they will use their best judgment, based on the nature and urgency of the clinical situation, and may proceed with unblinding.

Contact information for the medical monitor (or appropriate backup) will be in a separate document.

If a subject's treatment assignment has been unblinded for a medical emergency or urgent clinical situation, the medical monitor will be notified within 24 hours of the unblinding event. The reason and the date of the unblinding will be documented clearly in the subject's study file. Information about the treatment assignment obtained from the unblinding will be maintained in a secure location with controlled access and will not be shared with Vertex, the CRO, or any site personnel (other than the physician treating the subject). In addition, the investigator will consider whether the clinical event that prompted unblinding will be considered an SAE, according to the regulatory definitions or criteria for SAEs, and if so, submit an SAE report to Vertex GPS or designee, per [Section 13.1.2](#).

Vertex GPS or designee will also unblind any SAE reports in compliance with regulatory reporting requirements. In addition, Vertex may, for matters relating to safety, unblind individual subjects at any time.

11 ASSESSMENTS

The schedule of assessments is shown in [Table 3-1](#), [Table 3-2](#), and [Table 3-3](#).

11.1 Subject and Disease Characteristics

Subject and disease characteristics include the following: demographics, medical and surgical history, height, and weight.

11.2 Pharmacokinetics

11.2.1 Blood Sampling

Blood samples will be collected from subjects for the evaluation of plasma concentrations of VX-548 and its metabolite, [REDACTED].

These samples may also be used for evaluations of other study medications (e.g., rescue medication, acetaminophen, hydrocodone), other metabolites of VX-548, for further evaluation of the bioanalytical method, and for analyses that provide information on the metabolic pathways used or impacted by VX-548.

Plasma concentration samples collected from subjects in the placebo treatment group will not be routinely analyzed.

All efforts will be made to obtain the PK samples at the exact nominal time relative to dosing. Acceptable windows for sampling times are shown in [Table 11-1](#). Samples collected outside of these acceptable windows will be considered protocol deviations. The following details will be recorded accurately in the source document on days of PK blood sample collection: date and time of administration of each dose; date and time of each of the PK blood samples; and date and time of the last meal taken before each dose.

Table 11-1 Acceptable Pharmacokinetic Sampling Windows

Sampling Time	Time From Scheduled Sampling Allowed
Predose	Any time on Day 1 after completion of eligibility assessments and before surgery
At 12, 24, and 36 hours after the first dose of study drug	Within 15 minutes before the next study drug dose
At all other time points after the first dose of study drug	Within \pm 30 minutes of scheduled time point

Note: Refer to [Table 3-2](#) and [Table 3-3](#) for pharmacokinetic sampling time points.

11.2.2 Processing and Handling of Pharmacokinetic Samples

Detailed procedures for the collection of blood samples and further procedures for processing and handling of samples for PK analysis will be in the Laboratory Manual.

11.2.3 Bioanalysis

Samples will be analyzed using a validated analytical method in compliance with Vertex or designee standard operating procedures. A description of the assay and validation data will be provided in separate reports.

11.3 Other Assessments

11.3.1 Verbal Categorical Rating Scale

In the postoperative period before randomization, VRS at rest will be completed upon request for the first dose of study drug for pain relief. Pain intensity will be recorded after a ≥ 3 -minute rest in bed in either the supine or up to approximately 15-degree head-up position.

If a subject does not meet the VRS and NPRS criteria ([Section 8.1](#)) within 4 hours after surgery completion, the subject will not be eligible for this study.

11.3.2 Patient Global Assessment of Study Drug

The PGA of study drug must be completed before the start of any other assessments scheduled at the same time point. Detailed procedures for the administration of the PGA of study drug will be provided in a separate document.

11.3.3 Exploratory Assessments: Pharmacogenomics

A blood sample (optional DNA sample) will be collected for potential exploratory evaluation of associations between DNA markers and health and disease, especially pain, for subjects who choose to participate in this assessment.

These data will be used for internal exploratory purposes. Detailed procedures for the collection of blood samples and additional procedures for processing and handling samples for pharmacogenomics analysis will be provided in a separate document.

11.4 Efficacy

11.4.1 Placebo and Pain Assessment Video Training

All subjects will complete placebo and pain assessment video training at the Screening Visit and on Day 1 prior to the surgical procedure.

11.4.2 Numeric Pain Rating Scale

NPRS will be completed at rest and during movement as follows:

- **NPRS at rest:** Pain intensity will be recorded after a ≥ 3 -minute rest in bed in either the supine or up to approximately 15-degree head-up position.
- **NPRS during movement:** Perform immediately after completion of NPRS at rest. Pain intensity will be recorded after the subject sits up in bed, unassisted, at an angle of approximately 45 degrees or more.

In the postoperative period before randomization, NPRS at rest will be completed after VRS at rest if the subject's pain is rated moderate or severe on the VRS at rest. If a subject does not meet the VRS and NPRS criteria ([Section 8.1](#)) within 4 hours after surgery completion, the subject will not be eligible for this study.

During the Treatment Period, subjects will report their pain intensity on the NPRS at rest at each scheduled time point through 48 hours after the first dose of study drug. Starting 8 hours after the first dose of study drug, subjects will also report their pain intensity on the NPRS during movement. In addition, pain intensity will be recorded on the NPRS at rest immediately before each administration of rescue medication ([Section 9.4.1.2](#)).

11.4.3 Double-stopwatch Assessment

At the time of first dose, 2 stopwatches will be started by the appropriate study site staff: 1 labeled “first perceptible pain relief” and the other labeled “meaningful pain relief”. Both stopwatches will be given to the subject at the same time. The subject will stop the “first perceptible pain relief” stopwatch when/if they first feel any pain relief and stop the “meaningful pain relief” stopwatch when/if they first feel relief that is “meaningful” to them. If the subject does not stop both stopwatches by 6 hours after the first dose, or receives rescue medication, the stopwatches will be stopped.

11.4.4 Use of Rescue Medications

Guidelines on administration of ibuprofen as rescue medication are included in [Section 9.4.1.2](#). Rescue medication is permitted for pain relief upon subject’s request. A record will be kept of all rescue medication use, and an unscheduled NPRS at rest will be completed immediately before each administration of rescue medication.

11.5 Safety

Safety evaluations will include AEs, clinical laboratory assessments, clinical evaluation of vital signs, standard 12-lead ECGs, and physical examinations (PEs).

11.5.1 Adverse Events

All AEs will be assessed, documented, and reported in accordance with current ICH E6 GCP Guidelines. [Section 13.1](#) outlines the definitions, collection periods, criteria, and procedures for documenting, grading, and reporting AEs.

11.5.2 Clinical Laboratory Assessments

Blood and urine samples for clinical laboratory assessments will be collected as shown in [Table 3-1](#).

Laboratory test results that are abnormal and considered clinically significant will be reported as AEs (see [Section 11.5.1](#)).

The safety laboratory test panels are shown in [Table 11-2](#).

Table 11-2 Safety Laboratory Test Panels

Serum Chemistry	Hematology	Urinalysis ^a
Glucose	Hemoglobin	Urobilinogen
Blood urea nitrogen ^b	Platelets	Urine protein
Creatinine	Leukocytes	pH
Sodium	Differential (percent):	Urine blood
Potassium	Eosinophils	Specific gravity
Calcium	Basophils	Urine ketones
Chloride	Neutrophils	Urine bilirubin
Magnesium	Lymphocytes	Urine glucose
Bicarbonate	Monocytes	
Phosphate		
Total bilirubin		
Direct bilirubin		
Alkaline phosphatase		
Aspartate transaminase		
Alanine transaminase		
Lipase	Coagulation	
Gamma-glutamyl transferase	Activated partial thromboplastin time	
Protein	Prothrombin time	
Albumin	Prothrombin time International	
Creatine kinase	Normalized Ratio	
Urate		

^a If urinalysis results are positive for protein or blood, microscopic examination of urine will be performed and results provided for leukocytes, erythrocytes, crystals, bacteria, and casts.

^b If blood urea nitrogen cannot be collected, urea may be substituted.

Clinical laboratory assessments during screening must have no clinically significant findings that preclude participation in the study, as judged by the investigator, for a subject to receive study drug on Day 1.

Additional Tests at Screening: The following additional tests will be performed during screening to assess eligibility:

- **Serology:** hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), and antibodies against human immunodeficiency viruses 1 and 2 (HIV-1/HIV-2 Abs)
- **Serum Follicle-stimulating Hormone (FSH):** Serum FSH will be tested at the Screening Visit for female subjects who are suspected to be postmenopausal. For a subject to be considered of non-childbearing potential, the serum FSH levels will be within the laboratory's range for postmenopausal females.
- **Pregnancy Testing:** All female subjects will have a serum β -human chorionic gonadotropin (β -hCG) test during the Screening Visit. Female subjects of childbearing potential (as defined in Section 11.5.5.1), will also have a urine β -hCG test on Day 1 before admission. Both the serum and urine β -hCG test must be negative to receive study drug.
- **Drug and Alcohol Screening:** Drug screening for opioids, methadone, cannabinoids, cocaine, amphetamines/methamphetamines, barbiturates, and benzodiazepines will be assessed by a urine test. Alcohol screening will be assessed by a urine, blood, or breath test. Subjects may undergo random urine drug screen and alcohol testing if deemed appropriate by the investigator. Drug and alcohol screen results must be negative for a subject to receive study

drug. A positive drug screen for a known prescribed concomitant medication that is not otherwise exclusionary (e.g., benzodiazepines) will not disqualify subjects; however, marijuana (or any cannabis derivative) will not be allowed.

Additional evaluations: Additional clinical laboratory evaluations will be performed at other times if judged to be clinically appropriate.

For purposes of study conduct, only laboratory tests done in the central laboratory may be used, with the following exceptions:

- Day 1 (pre-procedure) drug and alcohol (breath) tests and urine β -hCG pregnancy tests will be assessed by staff onsite.
- Local laboratories may be used to repeat a screening assessment to determine eligibility on Day 1 (pre-procedure) if there is clear evidence of laboratory error ([Section 9.1.1.1](#)) in the central laboratory assessment.
- Local laboratories may be used at the discretion of the local investigator for management of urgent medical issues. If a local laboratory test value is found to be abnormal and clinically significant, it will be verified by the central laboratory as soon as possible after the investigator becomes aware of the abnormal result. If it is not possible to send a timely specimen to the central laboratory (e.g., the subject was hospitalized elsewhere), the investigator may base the assessment of an AE on the local laboratory value.

11.5.3 Physical Examinations and Vital Signs

A PE of all body systems and vital signs assessment will be performed at screening and select study visits. At other visits, symptom-directed PEs and symptom-directed vital signs assessments can be performed at the discretion of the investigator or healthcare provider.

A PE includes a review of the following systems: head, neck, and thyroid; eyes, ears, nose, and throat (EENT); respiratory; cardiovascular; lymph nodes; abdomen; skin; musculoskeletal; and neurological. Breast, anorectal, and genital examinations will be performed when medically indicated. After screening, any clinically significant abnormal findings in PEs will be reported as AEs.

A focused PE of the operative site will be performed in order to assess wound healing. Vital signs include blood pressure (systolic and diastolic), temperature, pulse rate, respiration rate, and oxygen saturation (SpO₂). The subject will be instructed to rest for at least 5 minutes before vital signs are assessed.

11.5.4 Electrocardiograms

Standard 12-lead ECGs will be performed using a machine with printout. Additional standard 12-lead ECGs will be performed at any other time if clinically indicated. The performance of all ECGs will adhere to the following guidelines:

- The ECG will be done before any other procedures that may affect heart rate, such as blood draws.
- The subject will be instructed to rest for at least 5 minutes before having an ECG.
- The test should be performed in the supine position

A printout of the ECG traces will be made for safety review by the investigator and maintained with source documentation. Clinically significant ECG abnormalities occurring during the study through the Safety Follow-up Visit will be recorded as AEs.

To ensure safety of the subjects, a qualified individual at the study site will make comparisons to baseline measurements. If the QTcF is increased by >60 msec from the baseline or an absolute QTcF value is ≥ 500 msec for any scheduled ECG, 2 additional ECGs will be performed approximately 2 to 4 minutes apart to confirm the original measurement. If either of the QTcF values from these repeated ECGs remains above the threshold value (>60 msec from baseline or ≥ 500 msec), a single ECG will be repeated at least hourly until QTcF values from 2 successive ECGs fall below the threshold value that triggered the repeat measurement. A subject with a QTcF value above the threshold value will discontinue dosing.

11.5.5 Contraception and Pregnancy

The effects of VX-548 on conception, pregnancy, and lactation in humans are not known. Refer to the VX-548 Investigator's Brochure for additional details.

11.5.5.1 Contraception

Study participation requires a commitment from subjects and their partners to use methods of contraception, as outlined in [Table 11-3](#), from the Screening Visit through 30 days after the last dose of study drug.

Table 11-3 Contraceptive Requirements

Male subjects and their female (non-study) partners	<p>Male subjects must use a condom (with spermicide, if available) from the Screening Visit through 30 days after the last dose of study drug.</p> <p>In addition, at least 1 of the following acceptable methods must be used as a couple:^a</p> <ul style="list-style-type: none"> • Male vasectomy 6 months or more previously, with a documented negative post-vasectomy semen analysis for sperm • Female bilateral tubal ligation performed at least 6 months previously • Female continuous use of an intrauterine device for at least 90 days before the first dose of study drug, throughout study drug treatment, and until 30 days after the last dose of study drug. • Female hormonal contraceptives, if successfully used for at least 60 days before the first dose of study drug, throughout study drug treatment, and until 30 days after the last dose of study drug.
Female subjects and their male (non-study) partners	<p>Male (non-study) partners must use a condom (with spermicide, if available) from the Screening Visit through 30 days after the last dose of study drug.</p> <p>In addition, at least 1 of the following acceptable methods must be used as a couple:^{a,b}</p> <ul style="list-style-type: none"> • Male vasectomy 6 months or more previously, with a documented negative post-vasectomy semen analysis for sperm • Female bilateral tubal ligation performed at least 6 months previously • Female continuous use of an intrauterine device for at least 90 days before the first dose of study drug, throughout study drug treatment, and until 30 days after the last dose of study drug.

^a Male subjects must use a condom to avoid exposing a potential fetus to study drug via the seminal fluid. Female condom is not an acceptable method due to the increased risk of tearing when the female and male condoms are used at the same time.

^b The effects of VX-548 on the PK of hormonal contraceptives are not known. A female subject of childbearing potential using hormonal contraceptives does not need to stop taking hormonal contraceptives; however, they are NOT permitted as an approved form of contraception for female subjects.

Contraception for the couple is waived for the following:

- True abstinence for the subject, when this is consistent with the preferred and usual lifestyle of the subject. True abstinence must be practiced from the Screening Visit through 30 days after the last dose of study drug. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
- If the male is infertile (e.g., bilateral orchiectomy). Infertility may be documented through examination of a semen specimen.
- If the female is of non-childbearing potential. To be considered of non-childbearing potential, the female must meet at least 1 of the following criteria:
 - o Postmenopausal: Amenorrheic for at least 12 consecutive months and a serum FSH level within the laboratory's reference range for postmenopausal females
 - o Documented bilateral oophorectomy and/or hysterectomy
- Same biological sex relationships.

Additional notes:

- Male subjects must not donate sperm from the first study drug dose, throughout the study, and for 90 days following the last dose of study drug.
- Male and female subjects who are not sexually active at the time of screening must agree to follow the contraceptive requirements of this study if they become sexually active.
- If applicable, additional contraception requirements may need to be followed according to local regulations and/or requirements.

Unique situations that may not fall within the above specifications may be discussed with the Vertex medical monitor or designee on an individual basis.

11.5.5.2 Pregnancy

Subjects will be counseled to inform the investigator of any pregnancy that occurs during study treatment and for 90 days after the last dose of study drug.

If a subject, or the female partner of a male subject, becomes pregnant while participating in the study, the study drug will be permanently discontinued immediately. The investigator will 1) notify the medical monitor and Vertex GPS within 24 hours of the site's knowledge of the subject's (or partner's) pregnancy, and 2) send the Pregnancy Information Collection Form to Vertex GPS.

A subject (or their partner, if relevant) who becomes pregnant while on study will be followed until the end of the pregnancy only if on blinded treatment, or if they have been unblinded and have received active drug. The infant will be followed for 1 year after birth, provided informed consent is obtained. A separate ICF will be provided to explain these follow-up activities. Pregnancy itself is not an AE.

12 STATISTICAL ANALYSIS

This section presents a summary of the principal features of the planned efficacy, safety, and PK analyses for the study. Safety and efficacy analysis details will be provided in the statistical analysis plan (SAP), and PK analysis details will be provided in the clinical pharmacology analysis plan (CPAP). Both the SAP and CPAP will be finalized before clinical data lock.

Final analyses will take place after all subjects have completed the study, all data have been entered in the clinical study database, and the clinical data have been locked.

12.1 Sample Size and Power

The sample size calculation is based on the comparison between VX-548 and placebo on the primary endpoint. Assuming a standardized effect size of 0.8 for VX-548 (high or low dose) compared to placebo, 54 evaluable subjects per group would provide at least 90% power at a 2-sided significance level of 0.05. This sample size would allow a minimal detectable standardized effect size of 0.38 to achieve statistical significance between VX-548 (high or low dose) and placebo. With this sample size, a two-sided 95% CI for the estimated standard effect size will extend 0.38 from the observed standardized effect size, assuming the CI is based on the large sample z statistic. To allow for withdrawal of up to 15% of randomized subjects over 48 hours of treatment, the study will enroll and randomize approximately 256 subjects in total.

12.2 Analysis Sets

The following analysis sets are defined: All Subjects Set, Full Analysis Set (FAS), and Safety Set.

The All Subjects Set is defined as all subjects who have been randomized or have received at least 1 dose of study drug. This analysis set will be used in subject listings and disposition summary tables, unless otherwise specified.

The FAS is defined as all randomized subjects who have received at least 1 dose of study drug. The FAS is to be used in efficacy analyses in which subjects will be analyzed according to their randomized treatment group, unless otherwise specified.

The Safety Set is defined as all subjects who have received at least 1 dose of study drug. The Safety Set is to be used for all safety analyses in which subjects will be analyzed according to the treatment they received, unless otherwise specified.

12.3 Statistical Analysis

The primary objective of this study is to evaluate the efficacy of VX-548 doses in treating acute pain after an abdominoplasty.

This section presents a summary of the planned statistical analyses of efficacy and safety for this study. Methodological and related details (e.g., missing data) will be in the SAP.

12.3.1 General Considerations

All individual subject data for subjects who were randomized or received at least 1 dose of study drug will be presented in individual subject data listings.

Continuous variables will be summarized using the following descriptive summary statistics: the number of subjects (n), mean, SD, median, minimum value (min), and maximum value (max).

Categorical variables will be summarized using counts and percentages.

Baseline value, unless specified otherwise, will be defined as the most recent non-missing measurement (scheduled or unscheduled) collected before the first dose of study drug.

Treatment-emergent (TE) Period will include the time from the first dose of study drug in the Treatment Period to either (1) the Safety Follow-up, or (2) the date of the last dose + 16 days for subjects who do not have a Safety Follow-up.

12.3.2 Background Characteristics

Subject disposition (e.g., completed treatment, prematurely discontinued the treatment and the reason for discontinuation) will be summarized by treatment group.

Demographics and baseline characteristics (e.g., sex, age, race, ethnicity, weight, height, BMI, and pain intensity) will be summarized by treatment group. No statistical tests will be carried out to evaluate any baseline imbalance between treatment groups.

Medications used will be coded using the World Health Organization Drug Dictionary and summarized descriptively.

All data collected during dispensation of study drug (e.g., time of administration and number of tablets and capsules) will be presented in data listings only.

Additional details will be provided in the SAP.

12.3.3 Efficacy Analysis

Evaluation of the efficacy of VX-548 doses is the primary objective of this study. All efficacy endpoints will be analyzed based on the FAS. The analysis of the primary efficacy endpoint and secondary endpoints will only be between VX-548 and placebo. All analyses on comparisons between HB/APAP versus placebo will be exploratory.

12.3.3.1 Analysis of Primary Endpoint

The primary efficacy endpoint is the time-weighted SPID_{r0-48} after the first dose of study drug. The primary efficacy analysis will be based on an analysis of covariance (ANCOVA) model. The model will include SPID_{r0-48} as the dependent variable and treatment as a fixed effect, with stratification factors (i.e., site and baseline NPRS at rest) as covariates. If the model estimation does not converge, site will be removed from the model. The least squares means of difference versus placebo and the corresponding 95% CIs and *P* values will be presented.

Details will be provided in the SAP.

12.3.3.2 Analysis of Secondary Efficacy Endpoints

- Time-weighted SPID_{r0-24} after the first dose of study drug: analysis of this variable will be similar to the primary analysis.
- Proportions of subjects with $\geq 30\%$, $\geq 50\%$, and $\geq 70\%$ reduction in NPRS at rest at 48 hours after the first dose of study drug: These variables will be analyzed using the Cochran-Mantel-Haenszel test, stratified by baseline NPRS at rest.

All analyses of primary and secondary variables on comparisons between HB/APAP versus placebo will be exploratory, although similar to those between VX-548 versus placebo.

12.3.3.3 Multiplicity Adjustment

There is no multiplicity adjustment for the pairwise comparisons between different doses of VX-548 and placebo.

12.3.3.4 Missing Data Handling

For the primary analysis, NPRS at rest that were collected within 6 hours after a dose of rescue medication will be taken as missing and will be imputed using the pre-rescue NPRS at rest. Missing values due to early withdrawal will be imputed using the last non-missing observation carried forward before the calculation of SPID_{r0-48} values. Sensitivity analyses for handling missing data will be described in the SAP.

12.3.4 Safety Analysis

The overall safety profile of VX-548 will be assessed in terms of the following safety and tolerability endpoints:

- Incidence of treatment-emergent adverse events (TEAEs)
- Clinical laboratory values (i.e., hematology, serum chemistry, coagulation, and urinalysis)
- Standard 12-lead ECG outcomes
- Vital signs

Safety endpoints will be analyzed based on the Safety Set. For safety analyses, no statistical hypothesis testing will be conducted. Additional details will be provided in the SAP.

12.4 Interim Analysis

Not applicable

12.5 Data Monitoring Committee Analysis

Not applicable

12.6 Clinical Pharmacology Analysis

12.6.1 Pharmacokinetic Analysis

The PK of VX-548 and its metabolite, [REDACTED], will be determined by noncompartmental analysis and described using summary statistics. Preliminary review and analyses of the drug concentrations may be done before database lock under the conditions of masked identifications of the subject concentrations.

Details of the analyses will be in the CPAP.

12.6.2 Pharmacokinetic/Pharmacodynamic Analyses

A population PK analysis of plasma concentration versus time data of VX-548 and [REDACTED] may be performed using the nonlinear mixed-effects modeling approach. A population approach may also be used to investigate the exposure-response relationship for the efficacy and safety variables. A more detailed description of the methodology to be followed will be presented in the abbreviated modeling and simulation analysis plan (AMSAP). The results of the population PK and exposure-response analysis (if done) will be reported in a separate document.

13 PROCEDURAL, ETHICAL, REGULATORY, AND ADMINISTRATIVE CONSIDERATIONS

13.1 Adverse Event and Serious Adverse Event Documentation, Severity Grading, and Reporting

13.1.1 Adverse Events

13.1.1.1 Definition of an Adverse Event

An AE is defined as any untoward medical occurrence in a subject during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or worsening of a pre-existing condition (e.g., increase in its severity or frequency) after the ICF is signed.

An AE is considered serious if it meets the definition in [Section 13.1.2.1](#).

13.1.1.2 Clinically Significant Assessments

Study assessments including laboratory tests, ECGs, PEs, and vital signs will be assessed and those deemed to have clinically significant worsening from baseline will be documented as an AE. When possible, a clinical diagnosis for the study assessment will be provided, rather than the abnormal test result alone (e.g., urinary tract infection, anemia). In the absence of a diagnosis,

the abnormal study assessment itself will be listed as the AE (e.g., bacteria in urine or decreased hemoglobin).

An abnormal study assessment is considered clinically significant if the subject has 1 or more of the following:

- Concomitant signs or symptoms related to the abnormal study assessment
- Further diagnostic testing or medical/surgical intervention
- A change in the dose of study drug or discontinuation from the study

Repeat testing to determine whether the result is abnormal, in the absence of any of the above criteria, does not necessarily meet clinically significant criteria. The determination of whether the study assessment results are clinically significant will be made by the investigator.

A laboratory value that is Grade 4 will not automatically be an SAE. A Grade 4 laboratory value will be an SAE if the subject's clinical status indicates a life-threatening AE.

13.1.1.3 Documentation of Adverse Events

All AEs will be collected from the time the ICF is signed until the following times:

- For subjects who do not enroll: until time of screen failure (e.g., screen failure, withdrawal of consent)
- For enrolled subjects who have a Safety Follow-up Visit: through the Safety Follow-up Visit
- For enrolled subjects who do not have a Safety Follow-up Visit, 16 days after the last dose of study drug.

All subjects will be queried, using nonleading questions, about the occurrence of AEs at each study visit. When possible, a constellation of signs and/or symptoms will be identified as 1 overall event or diagnosis. All AEs for enrolled subjects will be recorded in the case report form (CRF) and source document. AEs for subjects who are screened but not subsequently enrolled will be recorded only in the subject's source documents. The following data will be documented for each AE:

- Description of the event
- Classification of "serious" or "nonserious"
- Date of first occurrence and date of resolution (if applicable)
- Severity
- Causal relationship to study drug(s)
- Action taken
- Outcome
- Concomitant medication or other treatment given

13.1.1.4 Adverse Event Severity

The investigator will determine and record the severity of all serious and nonserious AEs. The guidance available at the following website will be consulted: Common Terminology Criteria for

Adverse Events (CTCAE), Version 5.0, Cancer Therapy Evaluation Program, http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (Accessed September 2019). The severity of an AE described by a term that does not appear in the CTCAE will be determined according to the definitions in Table 13-1.

Table 13-1 Grading of AE Severity

Classification	Description
Grade 1 (Mild)	Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
Grade 2 (Moderate)	Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental ADL ^a
Grade 3 (Severe)	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL ^b
Grade 4 (Life-threatening)	Life-threatening consequences; urgent intervention indicated
Grade 5 (Death)	Death related to adverse event

Source: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (Accessed September 2019)

ADL: activities of daily living; AE: adverse event

Note: A semi-colon indicates 'or' within the description of the grade.

^a Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.

^b Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

13.1.1.5 Adverse Event Causality

Every effort will be made by the investigator to assess the relationship of the AE, if any, to the study drug(s). Causality will be classified using the categories in Table 13-2.

Table 13-2 Classifications for AE Causality

Classification	Definition
Related	There is an association between the event and the administration of investigational study drug, a plausible mechanism for the event to be related to the investigational study drug and causes other than the investigational study drug have been ruled out, and/or the event reappeared on re-exposure to the investigational study drug.
Possibly related	There is an association between the event and the administration of the investigational study drug and there is a plausible mechanism for the event to be related to investigational study drug, but there may also be alternative etiology, such as characteristics of the subject's clinical status or underlying disease.
Unlikely related	The event is unlikely to be related to the investigational study drug and likely to be related to factors other than investigational study drug.
Not related	The event is related to an etiology other than the investigational study drug (the alternative etiology will be documented in the subject's medical record).

AE: adverse event

13.1.1.6 Study Drug Action Taken

The investigator will classify the study drug action taken with regard to the AE. The action taken will be classified according to the categories in [Table 13-3](#).

Table 13-3 Classifications for Study Drug Action Taken With Regard to an AE

Classification ^a	Definition
Dose not changed	Study drug dose not changed in response to an AE
Dose reduced	Study drug dose reduced in response to an AE
Drug interrupted	Study drug administration interrupted in response to an AE
Drug withdrawn	Study drug administration permanently discontinued in response to an AE
Not applicable	Action taken regarding study drug administration does not apply. “Not applicable” will be used in circumstances such as when the investigational treatment had been completed before the AE began and no opportunity to decide whether to continue, interrupt, or withdraw treatment is possible.

AE: adverse event

^a Refer to [Section 9.7](#) for directions regarding what drug actions are permitted per protocol.

13.1.1.7 Adverse Event Outcome

An AE will be followed until the investigator has determined and provided the final outcome. The outcome will be classified according to the categories in Table 13-4.

Table 13-4 Classifications for Outcome of an AE

Classification	Definition
Recovered/resolved	Resolution of an AE with no residual signs or symptoms
Recovered/resolved with sequelae	Resolution of an AE with residual signs or symptoms
Not recovered/not resolved (continuing)	Either incomplete improvement or no improvement of an AE, such that it remains ongoing
Fatal	Outcome of an AE is death. “Fatal” will be used when death is at least possibly related to the AE.
Unknown	Outcome of an AE is not known (e.g., a subject lost to follow up)

AE: adverse event

13.1.1.8 Treatment Given

The investigator ensures adequate medical care is provided to subjects for any AEs, including clinically significant laboratory values related to study drug. In addition, the investigator will describe whether any treatment was given for the AE. “Yes” is used if any treatment was given in response to an AE, and may include treatments such as other medications, surgery, or physical therapy. “No” indicates the absence of any kind of treatment for an AE.

13.1.2 Serious Adverse Events

13.1.2.1 Definition of a Serious Adverse Event

An SAE is any AE that meets any of the following outcomes:

- Fatal (death, regardless of cause, that occurs during participation in the study or occurs after participation and is suspected of being a delayed toxicity due to administration of the study drug)
- Life-threatening, such that the subject was at immediate risk of death from the reaction as it occurred

- Inpatient hospitalization or prolongation of hospitalization
- Persistent or significant disability/incapacity (disability is defined as a substantial disruption of a person's ability to conduct normal life functions)
- Congenital anomaly or birth defect
- Important medical event that, based upon appropriate medical judgment, may jeopardize the subject or may require medical or surgical intervention to prevent 1 of the outcomes listed above (e.g., an allergic bronchospasm requiring intensive treatment in an emergency room or at home)

If a subject has a hospitalization or procedure (e.g., surgery) for an event or condition that occurred before the subject signed the ICF, and the hospitalization or procedure was planned before the subject signed the ICF, the hospitalization or procedure will not be considered to indicate an SAE, unless an AE caused the hospitalization or procedure to be rescheduled sooner or to be prolonged relative to what was planned. In addition, hospitalizations clearly not associated with an AE (e.g., social hospitalization for purposes of respite care) will not be considered to indicate an SAE.

Clarification will be made between the terms “serious” and “severe” because they are not synonymous. The term “severe” is often used to describe the intensity (severity) of a specific event, as in mild, moderate, or severe myocardial infarction. The event itself, however, may be of relatively minor medical significance, such as a severe headache. This is not the same as “serious”, which is based on subject/event outcome or action described above, and is usually associated with events that pose a threat to a subject's life or functioning. Seriousness, not severity, serves as a guide for defining expedited regulatory reporting obligations.

13.1.2.2 Reporting and Documentation of Serious Adverse Events

All SAEs that occur after obtaining informed consent through the Safety Follow-up Visit, regardless of causality, will be reported by the investigator to Vertex GPS **within 24 hours of identification**. In addition, all SAEs that occur after the Safety Follow-up Visit and are considered related to study drug(s) will be reported to Vertex GPS **within 24 hours of identification**.

For SAEs that occur after obtaining informed consent through the Safety Follow-up Visit, the SAE Form will be completed for new/initial events as well as to report follow-up information on previously reported events. Investigators are asked to report follow-up information as soon as it becomes available to ensure timely reporting to health authorities.

Please send completed SAE Forms to Vertex GPS via:

[REDACTED]

[REDACTED]

For technical issues related to submitting the form, contact telephone: [REDACTED]

SAEs that occur after the Safety Follow-up Visit and are considered related to study drug(s) will be recorded on the Vertex Clinical Trial Safety Information Collection Form (hereafter referred to as the “SAE Form”) using a recognized medical term or diagnosis that accurately reflects the event. SAEs will be assessed by the investigator for relationship to the investigational study drug(s) and possible etiologies. On the SAE Form, relationship to study drug(s) will be assessed

only as related (includes possibly related) or not related (includes unlikely related), and severity assessment will not be required. For the purposes of study analysis, if the event has not resolved at the end of the study reporting period, it will be documented as ongoing. For purposes of regulatory safety monitoring, the investigator is required to follow the event to resolution and report the outcome to Vertex using the SAE Form.

13.1.2.3 Expedited Reporting and Investigator Safety Letters

Vertex, as study sponsor, is responsible for reporting suspected, unexpected, serious adverse reactions involving the study drug(s) to all regulatory authorities, IEC, and participating investigators in accordance with current ICH E2A Guidelines and/or local regulatory requirements, as applicable. In addition, Vertex, or authorized designee, will be responsible for the submission of safety letters to central IECs.

It is the responsibility of the investigator or designee to promptly notify the local IRB/IEC of all unexpected serious adverse drug reactions involving risk to human subjects.

13.2 Administrative Requirements

13.2.1 Product Complaints

A product complaint is defined as any verbal or written communication addressed to Vertex, or designee, of inquiry or dissatisfaction with the identity, strength, quality, or purity of a released drug product, IMP, or medical device. In addition, suspected counterfeit/falsified product is considered a product complaint.

Product complaints are to be reported to Vertex.

13.2.2 Ethical Considerations

The study will be conducted in accordance with the current ICH E6 GCP Guidelines, which are consistent with the ethical principles founded in the Declaration of Helsinki, and in accordance with local applicable laws and regulations. The IRB/IEC will review all appropriate study documentation to safeguard the rights, safety, and well-being of the subjects. The study will be conducted only at sites where IRB/IEC approval has been obtained. The protocol, Investigator's Brochure, sample ICF, advertisements (if applicable), written information given to the subjects (including diary cards), safety updates, annual progress reports, and any revisions to these documents will be provided to the IRB/IEC by the investigator or Vertex, as allowable by local applicable laws and regulations.

13.2.3 Subject Information and Informed Consent

After the study has been fully explained, written informed consent will be obtained from the subject or legal representative or guardian (if applicable) before study participation. The method of obtaining and documenting the informed consent and the contents of the consent will comply with current ICH E6 GCP Guidelines and all applicable laws and regulations and will be subject to approval by Vertex or its designee.

13.2.4 Investigator Compliance

No modifications to the protocol will be made without the approval of both the investigator and Vertex. Changes that significantly affect the safety of the subjects, the scope of the investigation, or the scientific quality of the study (i.e., efficacy assessments) will require IRB/IEC notification before implementation, except where the modification is necessary to eliminate an apparent

immediate hazard to human subjects. Vertex will submit all protocol modifications to the required regulatory authorities.

When circumstances require an immediate departure from procedures set forth in the protocol, the investigator will contact Vertex to discuss the planned course of action. If possible, contact will be made before the implementation of any changes. Any departures from the protocol will be fully documented in the source documentation and in a protocol deviation log.

13.2.5 Access to Records

The investigator will make the office and/or hospital records of subjects enrolled in this study available for inspection by Vertex or its representative at the time of each monitoring visit and for audits. The records will also be available for direct inspection, verification, and copying, as required by applicable laws and regulations, by officials of the regulatory health authorities (FDA and others). The investigator will comply with applicable privacy and security laws for use and disclosure of information related to the research set forth in this protocol.

13.2.6 Subject Privacy

To maintain subject confidentiality and to comply with applicable data protection and privacy laws and regulations, all CRFs, study reports, and communications relating to the study will identify subjects by assigned subject numbers, and access to subject names linked to such numbers will be limited to the site and the study physician and will not be disclosed to Vertex. As required by applicable laws and regulations in the countries in which the study is being conducted, the investigator will allow Vertex and/or its representatives access to all pertinent medical records to allow for the verification of data gathered in the CRFs/SAE Forms and the review of the data collection process. The FDA and regulatory authorities in other jurisdictions, including the IRB/IEC, may also request access to all study records, including source documentation, for inspection.

For sites participating in the US, and in accordance with the Health Insurance Portability and Accountability Act (HIPAA) and associated regulations, an executed HIPAA authorization will be obtained by the site from each subject (or the legal representative of the subject) before research activities may begin. Each HIPAA authorization will comply with all HIPAA requirements including authorization allowing the site access to and use of the subject's personally identifiable health information, authorization for the site to disclose such information to Vertex, the FDA, and other parties requiring access under the protocol, and statements as to the purpose for which such information may be used and for how long.

13.2.7 Record Retention

The investigator will maintain all study records according to current ICH E6 GCP Guidelines and/or applicable local regulatory requirement(s), whichever is longest, as described in the Clinical Trial Agreement. If the investigator withdraws from the responsibility of keeping the study records, custody will be transferred to a person willing to accept the responsibility and Vertex will be notified.

13.2.8 Study Termination

At any time, Vertex may terminate this study in its entirety or may terminate this study at any particular site. In addition, for reasonable cause, either the investigators or their IRBs/IECs may terminate the study at their center.

Conditions that may lead to reasonable cause and warrant termination include, but are not limited to:

- Subject or investigator noncompliance
- Unsatisfactory subject enrollment
- Lack of adherence to protocol procedures
- Lack of evaluable and/or complete data
- Potentially unacceptable risk to study subjects
- Decision to modify drug development plan
- Decision by the FDA or other regulatory authority

Written notification that includes the reason for the clinical study termination is required.

13.2.9 End of Study

The end of study is defined as the last scheduled visit (or scheduled contact) of the last subject.

13.3 Data Quality Assurance

Vertex or its designated representative will conduct a study site visit to verify the qualifications of each investigator, inspect clinical study site facilities, and inform the investigator of responsibilities and procedures for ensuring adequate and correct study documentation per current ICH E6 GCP Guidelines.

The investigator is required to prepare and maintain adequate and accurate case histories designed to record all observations and other data pertinent to the study for each subject. Study data for each enrolled subject will be entered into a CRF by study site personnel using a secure, validated, web-based electronic data capture (EDC) application. Vertex will have read-only access to site-entered clinical data in the EDC application.

Instances of missing, discrepant, or uninterpretable data will be queried with the investigator for resolution. Any changes to study data will be made to the CRF and documented in an audit trail, which will be maintained within the clinical database.

13.4 Monitoring

The study will be monitored by Vertex or its designee in accordance with written procedures. Monitoring and auditing procedures developed or approved by Vertex for these activities comply with GCP regulatory requirements and guidelines. The monitoring strategy may include onsite, remote, and central monitoring activities, in accordance with local regulations. The study site monitor will ensure that the investigation is conducted according to the protocol design and regulatory requirements.

13.5 Electronic Data Capture

Vertex will provide the study sites with secure access to and training on the EDC application sufficient to permit study site personnel to enter or correct information in the CRFs on the subjects for which they are responsible.

A CRF will be completed for each enrolled study subject. It is the investigator's responsibility to ensure the accuracy, completeness, clarity, and timeliness of the data reported in the subject's

CRF. Source documentation supporting the CRF data will indicate the subject's participation in the study and will document the dates and details of study procedures, AEs, other observations, and subject status.

The investigator, or designated representative, will complete the CRF as soon as possible after information is collected.

The audit trail entry will show the user's identification information and the date and time of any correction. The investigator will provide formal approval of all the information in the CRFs, including any changes made to them, to endorse the final submitted data for the subjects for whom the investigator is responsible.

Vertex will retain the CRF data and corresponding audit trails. A copy of the final archival CRF in the form of a compact disc or other electronic media will be placed in the investigator's study file.

13.6 Confidentiality and Disclosure

Any and all scientific, commercial, and technical information disclosed by Vertex in this protocol or elsewhere will be considered the confidential and proprietary property of Vertex. The investigator shall hold such information in confidence and shall not disclose the information to any third party except to such of the investigator's employees and staff as have been made aware that the information is confidential and who are bound to treat it as such and to whom disclosure is necessary to evaluate that information. The investigator shall not use such information for any purpose other than determining mutual interest in performing the study and, if the parties decide to proceed with the study, for the purpose of conducting the study.

The investigator understands that the information developed from this clinical study will be used by Vertex in connection with the development of the study drug and other drugs and diagnostics, and therefore may be disclosed as required to other clinical investigators, business partners and associates, the FDA, and other government agencies. The investigator also understands that, to allow for the use of the information derived from the clinical study, the investigator has the obligation to provide Vertex with complete test results and all data developed in the study.

13.7 Publications and Clinical Study Report

13.7.1 Publication of Study Results

Vertex is committed to reporting the design and results of all clinical studies in a complete, accurate, balanced, transparent, and timely manner, consistent with Good Publication Practices (GPP3).³⁴

Publication Planning: Vertex staff along with the lead principal investigators, the steering committee, and/or the publication committee will work together to develop a publication plan.

Authorship: Authorship of publications will be determined based on the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, which states that authorship should be based on the following 4 criteria³⁵:

1. Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data;
2. Drafting of the article or revising it critically for important intellectual content;

3. Final approval of the version to be published; and
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All authors must meet conditions 1, 2, 3, and 4. All persons designated as authors should qualify for authorship, and all those who qualify should be listed. Contributions such as medical writing, enrollment of subjects, acquisition of funding, collection of data, or general supervision of the research group, alone, do not justify authorship.

Contributors: Contributors who meet fewer than all 4 of International Committee of Medical Journal Editors criteria for authorship will not be listed as authors, but their contribution will be acknowledged and specified either as a group (e.g., “study investigators”) or individually (e.g., “served as scientific advisor”).

Publication Review: As required by a separate clinical study agreement, Vertex must have the opportunity to review all publications, including any manuscripts, abstracts, oral/slide presentations, and book chapters regarding this study before submission to congresses or journals for consideration.

13.7.2 Clinical Study Report

A clinical study report (CSR), written in accordance with the current ICH E3 Guideline, will be submitted in accordance with local regulations.

14 REFERENCES

- 1 Payne R. Limitations of NSAIDs for pain management: toxicity or lack of efficacy? *J Pain*. 2000;1(3 Suppl):14-8.
- 2 Centers for Disease Control and Prevention, Hedegaard H, Minino AM, Warner M. Drug overdose deaths in the United States, 1999-2018,. *NCHS Data Brief*.. 2020;No. 356:
- 3 Centers for Disease Control and Prevention. Vital statistics rapid release: Provisional Drug Overdose Death Counts Available at: <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#ref7>. Accessed 10 December 2020.
- 4 European Monitoring Centre for Drugs and Drug Addiction. European drug report: Trends and developments. Lisbon, Portugal: 2020.
- 5 Taneja A, Della Pasqua O, Danhof M. Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm. *Eur J Clin Pharmacol*. 2017;73(10):1219-36.
- 6 United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. 2008. Novel Drug Approvals. Available at: <https://web.archive.org/web/20110507202042/http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM081805.pdf>. Accessed 01 March 2019.
- 7 United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. 2009. Novel Drug Approvals Available at: <https://web.archive.org/web/20110507202020/http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM091096.pdf>. Accessed 01 March 2019.
- 8 United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. 2010. Novel Drug Approvals. Available at: <https://web.archive.org/web/20120301171618/http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM242677.pdf>. Accessed 01 March 2019.
- 9 United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. 2011-2014. Novel Drug Approvals. Available at: <https://wayback.archive-it.org/7993/20170722032043/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm>. Accessed 01 March 2019.
- 10 United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. 2015-2019. Novel Drug Approvals. Available at: <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm629491.htm>. Accessed 01 March 2019.
- 11 England S. Voltage-gated sodium channels: the search for subtype-selective analgesics. *Expert Opin Investig Drugs*. 2008;17(12):1849-64.
- 12 Krafte D, Bannon A. Sodium channels and nociception: recent concepts and therapeutic opportunities. *Curr Opin Pharmacol*. 2008;8(1):50-6.
- 13 Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. *Nature*. 1996;379(6562):257-62.

- 14 Shields SD, Ahn HS, Yang Y, Han C, Seal RP, Wood JN, et al. Nav1.8 expression is not restricted to nociceptors in mouse peripheral nervous system. *Pain*. 2012;153(10):2017-30.
- 15 Amaya F, Decosterd I, Samad TA, Plumpton C, Tate S, Mannion RJ, et al. Diversity of expression of the sensory neuron-specific TTX-resistant voltage-gated sodium ion channels SNS and SNS2. *Mol Cell Neurosci*. 2000;15(4):331-42.
- 16 Blair NT, Bean BP. Roles of tetrodotoxin (TTX)-sensitive Na⁺ current, TTX-resistant Na⁺ current, and Ca²⁺ current in the action potentials of nociceptive sensory neurons. *J Neurosci*. 2002;22(23):10277-90.
- 17 Bucknill AT, Coward K, Plumpton C, Tate S, Bountra C, Birch R, et al. Nerve fibers in lumbar spine structures and injured spinal roots express the sensory neuron-specific sodium channels SNS/PN3 and NaN/SNS2. *Spine (Phila Pa 1976)*. 2002;27(2):135-40.
- 18 Faber CG, Lauria G, Merkies ISJ, Cheng X, Han C, Ahn HS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. *Proc Natl Acad Sci U S A*. 2012;109(47):19444-49.
- 19 Han C, Vasylyev D, Macala LJ, Gerrits MM, Hoeijmakers JG, Bekelaar KJ, et al. The G1662S Nav1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. *J Neurol Neurosurg Psychiatry*. 2014;85(5):499-505.
- 20 Abrahamsen B, Zhao J, Asante CO, Cendan CM, Marsh S, Martinez-Barbera JP, et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. *Science*. 2008;321(5889):702-5.
- 21 Roza C, Laird JM, Souslova V, Wood JN, Cervero F. The tetrodotoxin-resistant Na⁺ channel Nav1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. *J Physiol*. 2003;550(Pt 3):921-6.
- 22 Strickland IT, Martindale JC, Woodhams PL, Reeve AJ, Chessell IP, McQueen DS. Changes in the expression of Nav1.7, Nav1.8 and Nav1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. *Eur J Pain*. 2008;12(5):564-72.
- 23 Qiu F, Jiang Y, Zhang H, Liu Y, Mi W. Increased expression of tetrodotoxin-resistant sodium channels Nav1.8 and Nav1.9 within dorsal root ganglia in a rat model of bone cancer pain. *Neurosci Lett*. 2012;512(2):61-6.
- 24 Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. *Proc Natl Acad Sci U S A*. 2007;104(20):8520-5.
- 25 Rush AM, Cummins TR. Painful research: identification of a small-molecule inhibitor that selectively targets Nav1.8 sodium channels. *Molecular Interventions*. 2007;7(4):192-5.
- 26 Payne CE, Brown AR, Theile JW, Loucif AJ, Alexandrou AJ, Fuller MD, et al. A novel selective and orally bioavailable Nav 1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability. *Br J Pharmacol*. 2015;172(10):2654-70.
- 27 Vertex Pharmaceuticals Incorporated. VX-548 Investigator's Brochure.
- 28 United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Draft guidance for industry: Analgesic indications: developing drug and biological products. Rockville, MD: February 2014.

- 29 Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. *Br J Anaesth*. 2008;101(1):17-24.
- 30 Cooper SA, Desjardins PJ, Turk DC, Dworkin RH, Katz NP, Kehlet H, et al. Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations. *Pain*. 2016;157(2):288-301.
- 31 Srikandarajah S, Gilron I. Systematic review of movement-evoked pain versus pain at rest in postsurgical clinical trials and meta-analyses: a fundamental distinction requiring standardized measurement. *Pain*. 2011;152(8):1734-39.
- 32 Gilron I, Orr E, Tu D, O'Neill JP, Zamora JE, Bell AC. A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. *Pain*. 2005;113(1-2):191-200.
- 33 Mehlisch DR, Ardia A, Pallotta T. A controlled comparative study of ibuprofen arginate versus conventional ibuprofen in the treatment of postoperative dental pain. *J Clin Pharmacol*. 2002;42(8):904-11.
- 34 Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good publication practice for communicating company-sponsored medical research: GPP3. *Ann Intern Med*. 2015;163(6):461-4.
- 35 International Committee of Medical Journal Editors (ICMJE). December 2017. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Available at: <http://www.icmje.org/recommendations/>. Accessed 03 August 2018.

15 PROTOCOL SIGNATURE PAGES

15.1 Sponsor Signature Page

Protocol #:	VX21-548-102	Version #:	4.0	Version Date:	21 January 2022
Study Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-dose Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty					

This clinical study protocol has been reviewed and approved by the sponsor.

15.2 Investigator Signature Page

Protocol #: VX21-548-102	Version #: 4.0	Version Date: 21 January 2022
Study Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-dose Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty		

I have read Protocol VX21-548-102, Version 4.0, and agree to conduct the study according to its terms. I understand that all information concerning VX-548 and this protocol supplied to me by Vertex Pharmaceuticals Incorporated (Vertex) is confidential.

Printed Name

Signature

Date